[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 9457
1. Shaheen N: Barrett Esophagus: Disease Management and Patient Perceptions. Gastroenterol Hepatol (N Y); 2006 Jul;2(7):468-470

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett Esophagus: Disease Management and Patient Perceptions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2005 Dec 14;11(46):7290-5 [16437630.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4478-82 [16002837.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):429-36 [16083700.001]
  • (PMID = 28289347.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Ginsberg G: Endoluminal Therapies for Barrett's Esophagus and Dysplasia. Gastroenterol Hepatol (N Y); 2006 Mar;2(3):165-167

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoluminal Therapies for Barrett's Esophagus and Dysplasia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Apr;118(4):670-7 [10734018.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):682-8 [11726842.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jul;1(4):241-5 [15017662.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jul;1(4):258-63 [15017666.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • (PMID = 28286444.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Rastogi A, Sharma P: Short-Segment Barrett's Esophagus and Adenocarcinoma. Gastroenterol Hepatol (N Y); 2006 Feb;2(2):134-139

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-Segment Barrett's Esophagus and Adenocarcinoma.
  • Barrett's esophagus is a known risk factor for the development of adenocarcinoma of the esophagus and esophagogastric junction.
  • Based on the length of the columnar segment at endoscopy, Barrett's esophagus has been arbitrarily separated into two broad categories: long-segment and short-segment.
  • The rapid rise in the incidence of esophageal adenocarcinoma has generated sustained research interest in this lesion.
  • Studies have shown that although the prevalence of short-segment Barrett's esophagus is higher than that of long-segment Barrett's esophagus, the risk of developing dysplasia and adenocarcinoma may actually be lower in those patients with short segment Barrett's esophagus.
  • Nonetheless, both dysplasia and esophageal adenocarcinoma have been reported in patients with short-segment Barrett's esophagus, making this arbitrary distinction clinically unimportant.
  • The current surveillance guidelines remain the same for both short- and long-segment Barrett's esophagus.
  • Another key issue is differentiating short-segment Barrett's esophagus from intestinal metaplasia of the gastric cardia.
  • The latter is distinct from esophageal intestinal metaplasia (ie, Barrett's esophagus) and probably does not warrant surveillance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1992 Jun;33(6):733-7 [1624150.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Gastroenterology. 1984 Oct;87(4):927-33 [6468881.001]
  • [Cites] Am J Gastroenterol. 1999 Dec;94(12):3413-9 [10606296.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Gut. 2003 Jan;52(1):24-7 [12477754.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1541-6 [7557137.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):414-8 [9068460.001]
  • [Cites] Dig Dis Sci. 2002 Sep;47(9):2108-11 [12353864.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):277-85 [9922307.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1249-56 [2703113.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):559-65 [11323579.001]
  • [Cites] Gastrointest Endosc. 1987 Dec;33(6):413-6 [3443258.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):913-8 [10201456.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1378-82 [11374671.001]
  • [Cites] Gut. 1997 Nov;41(5):585-9 [9414961.001]
  • [Cites] Endoscopy. 1993 Nov;25(9):652-4 [8119225.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1930-6 [12190156.001]
  • [Cites] Ann Intern Med. 2000 Apr 18;132(8):612-20 [10766679.001]
  • [Cites] Dig Dis Sci. 1997 Mar;42(3):597-602 [9073145.001]
  • [Cites] N Engl J Med. 1986 Aug 7;315(6):362-71 [2874485.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] J Gastroenterol. 2004 Jan;39(1):14-20 [14767729.001]
  • [Cites] Ann Surg. 1983 Oct;198(4):554-65 [6625723.001]
  • [Cites] Gut. 1997 Jun;40(6):710-5 [9245922.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):87-94 [11145256.001]
  • [Cites] Lancet. 1994 Dec 3;344(8936):1533-6 [7983953.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Gut. 1996 Jul;39(1):5-8 [8881798.001]
  • [Cites] Am J Gastroenterol. 1996 Aug;91(8):1507-11 [8759651.001]
  • [Cites] Gut. 2000 Jan;46(1):9-13 [10601047.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Gastrointest Endosc. 1994 Jan-Feb;40(1):111 [8163114.001]
  • [Cites] Gut. 1998 Jul;43(1):17-21 [9771400.001]
  • [Cites] Gut. 1991 Dec;32(12):1441-6 [1773946.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):289-93 [11522967.001]
  • [Cites] Dig Dis Sci. 1997 Mar;42(3):603-7 [9073146.001]
  • [Cites] Dig Dis Sci. 1992 Jan;37(1):137-43 [1728519.001]
  • [Cites] Br J Surg. 1988 Aug;75(8):760-3 [3167523.001]
  • [Cites] Am J Gastroenterol. 1994 May;89(5):670-80 [8172136.001]
  • [Cites] Gastrointest Endosc. 2005 Feb;61(2):226-31 [15729230.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1155-8 [8339208.001]
  • [Cites] Am J Gastroenterol. 1996 May;91(5):981-6 [8633592.001]
  • [Cites] Am J Gastroenterol. 1997 Nov;92(11):2012-6 [9362182.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):407-13 [9068459.001]
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] Gut. 1998 May;42(5):659-62 [9659160.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1033-6 [9672325.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1820-8 [8859198.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):294-301 [11522968.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):937-43 [10201460.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):857-9 [4033716.001]
  • (PMID = 28286441.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Barrett’s esophagus / adenocarcinoma / high-grade dysplasia / long-segment Barrett’s esophagus / low-grade dysplasia / short-segment Barrett’s esophagus
  •  go-up   go-down


Advertisement
4. Khaykin Y, Skanes A, Wulffhart ZA, Gula L, Whaley B, Oosthuizen R, Seabrook C, Beardsall M, Verma A: Intracardiac ECHO Integration with Three Dimensional Mapping: Role in AF Ablation. J Atr Fibrillation; 2008 Jul-Aug;1(2):32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary veins and the esophagus were rendered in 3D.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiovasc Electrophysiol. 2007 Mar;18(3):276-82 [17284265.001]
  • [Cites] Circulation. 1999 Sep 14;100(11):1203-8 [10484541.001]
  • [Cites] J Cardiovasc Electrophysiol. 2004 Nov;15(11):1335-40 [15574190.001]
  • [Cites] Circ Arrhythm Electrophysiol. 2008 Jun 1;1(2):110-9 [19808401.001]
  • [Cites] J Am Coll Cardiol. 2002 Aug 7;40(3):464-74 [12142112.001]
  • [Cites] Heart Rhythm. 2007 May;4(5):595-602 [17467627.001]
  • [Cites] Circulation. 2000 Nov 21;102(21):2619-28 [11085966.001]
  • (PMID = 28496579.001).
  • [Journal-full-title] Journal of atrial fibrillation
  • [ISO-abbreviation] J Atr Fibrillation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Ragan D, Starkschall G, McNutt T, Kaus M, Guerrero T, Stevens CW: Semiautomated four-dimensional computed tomography segmentation using deformable models. Med Phys; 2005 Jul;32(7Part1):2254-2261

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The contours of the right and left lungs, cord, heart, and esophagus were manually delineated on the end inspiration data set.
  • The algorithm failed to accurately contour the esophagus, a soft-tissue structure completely surrounded by tissue of similar density, without manual interaction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28493567.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; 4D imaging / Anatomy / CT segmentation / Cardiac dynamics / Computed radiography / Computed tomography / Computer software / Data sets / Heart / Hemodynamics / Lungs / Medical imaging / Medical treatment planning / Pneumodyamics, respiration / Radiation treatment / Tissues / biological organs / biological tissues / cardiology / computerised tomography / deformable models / image segmentation / lung / medical image processing / pneumodynamics
  •  go-up   go-down


6. St-Hilaire J, Lavoie C, Beaulieu F, Dagnault A, Morin F, Gingras L, Tremblay D, Beaulieu L: Sci-Fri PM: Planning-04: Dose escalation study using anatomy-based aperture IMRT and SPECT perfusion images for lung cancer. Med Phys; 2008 Jul;35(7Part3):3412-3413

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the case of non-small cell lung cancer, doses typically prescribed (60-66 Gy) are not sufficient to ensure a satisfactory tumor control probability.
  • Escalation was limited in two cases by the dose to the esophagus and in the other case by the presence of overdosages near beam entry ports.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512890.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Cancer / Computed tomography / Intensity modulated radiation therapy / Lungs / Medical imaging / Photons / Single photon emission computed tomography / Spatial analysis / Spatial dimensions
  •  go-up   go-down


7. Alcedo J, Ferrández A, Arenas J, Sopeña F, Ortego J, Sainz R, Lanas A: Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. Dis Esophagus; 2009 May 01;22(3):239-248

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28200121.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Tangen M, Andresen SJ, Moum B, Hauge T: [Stent insertion as palliation of cancer in the esophagus and cardia]. Tidsskr Nor Laegeforen; 2006 Jun 8;126(12):1607-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stent insertion as palliation of cancer in the esophagus and cardia].
  • [Transliterated title] Palliasjon med stent ved kreft i oesophagus og cardia.
  • BACKGROUND: The insertion of self-expanding metal stents (SEMS) for palliation of dysphagia in patients with malignant stenosis of the esophagus and cardia, is a well-established procedure.
  • The aim of this retrospective study was to evaluate the results of esophageal stenting in terms of functioning, need of retreatment and survival after stenting.
  • PATIENTS AND METHODS: 37 patients with unresectable esophageal and cardial carcinoma treated with SEMS between January 1997 and May 2004 were retrospectively analysed.
  • Tumor ingrowth or overgrowth was primarily treated with argon plasma coagulation (APC).
  • CONCLUSION: Insertion of SEMS in patients with inoperable carcinoma in esophagus and cardia should be regarded as a safe procedure.
  • [MeSH-major] Cardia. Esophageal Neoplasms / therapy. Palliative Care / methods. Stents. Stomach Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Deglutition Disorders / etiology. Deglutition Disorders / therapy. Esophageal Stenosis / etiology. Esophageal Stenosis / therapy. Esophagoscopy. Female. Humans. Male. Metals. Middle Aged. Prosthesis Implantation / adverse effects. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770371.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Metals
  •  go-up   go-down


9. Zhang P, Yang J, Hunt M, Mageras G: Dose correction strategy for the optimization of volumetric modulated arc therapya). Med Phys; 2010 Jun;37(6Part2):2441-2444

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical cases for brain, prostate, paraspinal, and esophagus are utilized to evaluate the method.
  • Applying dose correction during optimization saves planners 2-4 h in average in treatment planning, and has a positive impact on plan quality, evidenced by a noticeably higher PTV mean dose: 2.1%, 2.4%, 0.5%, and 9.3% of the corresponding prescription dose in the brain, esophagus, prostate, and paraspinal cases, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28513907.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Brain / Cancer / Computer simulation / Dose-volume analysis / Dosimetry / Intensity modulated radiation therapy / Medical treatment planning / Multileaf collimators / Optimization / Radiation treatment / Therapeutic applications, including brachytherapy / biological organs / dose calculation / dosimetry / optimisation / radiation therapy / treatment planning / volumetric arc modulated therapy
  •  go-up   go-down


10. Nguyen NT, Reavis KM, El-Badawi K, Hinojosa MW, Smith BR: Minimally invasive surgical enucleation or esophagogastrectomy for benign tumor of the esophagus. Surg Innov; 2008 Jun;15(2):120-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive surgical enucleation or esophagogastrectomy for benign tumor of the esophagus.
  • Experience in surgical resection of benign tumor of the esophagus is limited.
  • Authors performed a chart review of 5 patients who underwent minimally invasive surgical resection of benign esophageal tumor.
  • Main outcome measures included operative approaches, tumor's location and size, and outcomes.
  • Tumor location were middle esophagus (n = 1), distal esophagus (n = 2), and gastroesophageal junction (n = 2).
  • Surgical pathology showed leiomyoma in 3 patients and gastrointestinal stromal tumor in 2 patients.
  • Tumor size ranged from 1.1 to 10.5 cm.
  • There has been no tumor recurrence at a mean follow-up of 14 months.
  • Minimally invasive surgical enucleation or esophagogastrectomy for benign esophageal tumor is feasible and safe.
  • The optimal approaches should be tailored based on the location and size of the tumor.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / methods. Gastrectomy / methods. Minimally Invasive Surgical Procedures

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492731.001).
  • [ISSN] 1553-3506
  • [Journal-full-title] Surgical innovation
  • [ISO-abbreviation] Surg Innov
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Lustberg MB, Nuovo J, Thomas JP, Monk PJ 3rd, Kim S, Villalona-Calero M, Bekaii-Saab T: Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study. J Clin Oncol; 2009 May 20;27(15_suppl):2569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study.
  • The beneficial interactions of paclitaxel and carboplatin in upregulation of TP promise to make capecitabine more tumor specific and to provide the expected synergy.
  • METHODS: Patients with advanced solid tumors received carboplatin on day 1, paclitaxel on days 1, 8, 15 and capecitabine orally twice a day on days 8-21, every 4 weeks.
  • There were 10 confirmed responses [4 CR (esophagus, stomach, unknown primary and ampullary); 6 PRs (Pancreas (3), unknown primary, anal and esophagus] and stabilization of disease > 3 months in 12 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961879.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Haid A, Knauer M, Köberle-Wührer R, Wenzl E: Sentinel node biopsy in breast cancer: technique and indication. Wien Klin Wochenschr; 2005 Feb;117(4):121-128

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Sentinel node biopsy (SNB) has proved to be a useful and accurate procedure for lymph node staging in breast cancer and melanoma and should be standard of care in the treatment of these tumors.
  • In other malignancies (colon, rectum, stomach, esophagus, head and neck and thyroid, cervix uteri) it is still under investigation.
  • Accepted indications are uni- and multifocal tumors smaller than 3 cm without suspicious findings in the axilla, furthermore SNB is indicated in patients with large ductal carcinoma in situ (>2 cm) and/or with assumed microinvasion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28108807.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Keywords] NOTNLM ; Breast cancer / Indications / Sentinel node biopsy / Technique
  •  go-up   go-down


13. Nader D, Ketterl P, Kelly D, Flynn J, Stark JJ, Staren ED, Braun DP: Intratumoral chemotherapy as an adjunct to endobronchial brachytherapy. J Clin Oncol; 2009 May 20;27(15_suppl):7591

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intratumoral CTx consisted of CPt (1 mg/ml; 0.5-2.0 ml/session) injected into the entire visible tumor through a flexible 21 gauge needle through the bronchoscope.
  • In the other 2 pts, necrotic tissue occupying < 10 and 20% of the airway, cytologically negative for tumor was seen.
  • This approach offers the possibility of superior local tumor control while reducing toxicity to normal lung and esophagus as compared to conventional external beam radiation therapy modalities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Harada H, Nishio M, Murakami H, Ohyanagi F, Kozuka T, Ishikura S, Horiike A, Morota M, Nishimura T, Yamamoto N: Radiotherapy (RT) dose escalation study with concurrent cisplatin and S-1 in patients with inoperable stage III non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The target volume of RT included primary tumor and metastatic node only and elective nodal irradiation was not performed.
  • Dose constraints to the organs at risk were: the lung, V20 < 30%; the esophagus, mean dose < 34 Gy and V55 < 30%; the spinal cord, max dose < 50 Gy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963318.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Horgan AM, Darling G, Wong R, Visbal A, Guindi M, Jonker D, Liu G, Hornby J, Xu W, Knox JJ: Adjuvant sunitinib following chemoradiotherapy (CRT) and surgery for esophageal cancer: A phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant sunitinib following chemoradiotherapy (CRT) and surgery for esophageal cancer: A phase II trial.
  • : e15550 Background: Locally advanced esophageal cancer (LAEC) has a 5-year survival of < 30 %.
  • METHODS: Pts with LAEC of the thoracic esophagus or gastroesophageal junction, ECOG PS 0,1 and surgical candidates treated with: preoperative Irinotecan (65mg/m<sup>2</sup> initially, ammended to 50mg/m<sup>2</sup>) + Cisplatin (30mg/m<sup>2</sup>) on weeks 1,2,4,5,7,8 + concurrent conformal radiotherapy (50Gy/25 fractions) on weeks 4-8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962341.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Yoshii T, Tamai S, Aoyama N, Minamide J, Takagi S, Motohashi O, Nakayama N, Nishimura K, Takata K, Kameda Y: Clinical outcome of endoscopic mucosal resection (EMR) in clinical stage I (cSt I ) esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of endoscopic mucosal resection (EMR) in clinical stage I (cSt I ) esophageal cancer.
  • : e15569 Background: When a tumor invades to the muscularis mucosa or submucosal layer (T1a-MM or T1b, in Japan), cSt I esophageal cancer(EC) has 10-50%.
  • Endoscopic mucosal resection (EMR), which conserves the esophagus, is a minimally invasive and attractive therapeutic modality for such pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962323.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Lordick F, Meyer Zum Büschenfelde C, Thuss-Patience P, Röthling N, Geinitz H, Budach V, Schumacher G, Friess H, Siewert JR, Peschel C: Weekly cetuximab (CET) plus oxaliplatin (OX), infusional 5-fluorouracil (5-FU) and radiation therapy (RT) as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol; 2009 May 20;27(15_suppl):e15507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly cetuximab (CET) plus oxaliplatin (OX), infusional 5-fluorouracil (5-FU) and radiation therapy (RT) as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
  • All pts had locally advanced SCC (uT2-4, cNx, cM0-1a) of the cervical (n=1), the upper (n=5) or the distal (n=7) esophagus.
  • The anti-tumor activity of this regimen is promising and is being further investigated in an ongoing phase II study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962237.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Jain S, Gupta T, Reenadevi P, Agarwal J, Laskar SG, Shrivastava SK: Patterns of failures after definitive conformal radiation therapy for head and neck cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e17037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recurrent or persistent tumor volume (Vf) was defined using positron imaging tomography (PET) and surgical-pathologic findings, and analyzed using dose-volume histograms.
  • Two patients were detected to have distant metastases and two developed second malignancies, one out-field and other marginal with upper esophagus carcinoma at gradient zone of previous radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961804.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Yu J Sr, Han D, Zhong X, Mu D, Fu Z, Zhan G B, Zhang L, Zhang W: The optimal threshold of &lt;sup&gt;18&lt;/sup&gt;F-FLT PET and &lt;sup&gt;18&lt;/sup&gt;F-FDG PET to estimate the length of gross tumor volume in patients with squamous cell carcinoma of the thoracic esophagus verified by pathological examination. J Clin Oncol; 2009 May 20;27(15_suppl):e15665

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The optimal threshold of <sup>18</sup>F-FLT PET and <sup>18</sup>F-FDG PET to estimate the length of gross tumor volume in patients with squamous cell carcinoma of the thoracic esophagus verified by pathological examination.
  • : e15665 Background: To determine the optimal method of using 3-deoxy-3-<sup>18</sup>F-fluorothymidine (FLT) positron emission tomography (PET) to estimate gross tumor length in esophageal carcinoma, and compared with that of <sup>18</sup>F- fluorodeoxyglucose(FDG) PET.
  • METHODS: Twenty patients with esophageal squamous cell carcinoma treated with radical surgery were enrolled and detected by FLT PET, eighteen of them underwent FDG PET scan.
  • Gross tumor volumes (GTVs) were delineated using seven different methods with FLT PET: visual interpretation, standardized uptake value (SUV) 1.3, SUV 1.4, SUV 1.5, and 20% of maximum standard uptake value (SUVmax), 25% SUVmax,30% SUVmax, on FLT PET imaging, and three different methods with FDG PET: visual interpretation, SUV 2.5, and 40%SUVmax on FDG PET imaging.
  • The length of tumors on FLT PET scan were measured and recorded as L<sub>FLTvis</sub>, L<sub>FLT1.3</sub>, L<sub>FLT1.4</sub>, L<sub>FLT1.5</sub>, L<sub>FLT20%</sub>, L<sub>FLT25%</sub>, and L<sub>FLT30%</sub>, and FDG PET scan were measured and recorded as L<sub>FDGvis</sub>, L<sub>FDG2.5</sub>, and L<sub>FDG40%</sub>, respectively, and compared with the length of gross tumor in the resected specimen measured by pathological examination (L<sub>Path</sub>).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962763.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Saranovic D, Djuric-Stefanovic A, Ivanovic A, Masulovic D, Pesko P: Fluoroscopically guided insertion of self-expandable metal esophageal stents for palliative treatment of patients with malignant stenosis of esophagus and cardia: comparison of uncovered and covered stent types. Dis Esophagus; 2005 Sep 01;18(4):230-238

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluoroscopically guided insertion of self-expandable metal esophageal stents for palliative treatment of patients with malignant stenosis of esophagus and cardia: comparison of uncovered and covered stent types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203894.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Manickavasagam K, Servarayan CM, Rao S, Chandramohan A: Hedgehog signaling: Gli2 and its influence in squamous esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15596

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling: Gli2 and its influence in squamous esophageal cancer.
  • This study is to determine the expression pattern and the extent of Hh-signaling molecule(Gli2) in squamous cell carcinoma of oesophagus.
  • METHODS: A prospective immunohistochemical experimental study was done to identify the expression of Gli2 in 64 cases of squamous cell carcinoma of oesophagus.
  • These findings can be used for better prognosis of the patients by using stem cell therapy and HH pathway inhibitors in the treatment for squamous cell carcinomas of oesophagus.
  • To the best of our knowledge, this is the first study of expression of Gli2 in squamous cell carcinoma of oesophagus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962885.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kwong DL, Law SY, Tong DK, Wong KH, Nicholls J: COX-2 inhibition in combination with preoperative chemoradiation for CA esophagus. J Clin Oncol; 2009 May 20;27(15_suppl):e15607

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] COX-2 inhibition in combination with preoperative chemoradiation for CA esophagus.
  • : e15607 Background: Squamous cell carcinoma of the thoracic esophagus (ESCC) is often diagnosed in advanced stage.
  • The pCR rate in primary tumor was 51.7% (15/29 patients) and pCR rate in lymph nodes was 65.4% (17/26 patients).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962685.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Lurje G, Leers JM, Pohl A, Oezcelik A, Zhang W, Yang D, Hagen JA, DeMeester SR, DeMeester TR, Lenz HJ: Polymorphisms in epidermal growth factor (EGF) and proteinase activated receptor 1 (PAR-1) associated with tumor recurrence in localized adenocarcinoma (EA) of the esophagus treated with surgery alone. J Clin Oncol; 2009 May 20;27(15_suppl):4564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in epidermal growth factor (EGF) and proteinase activated receptor 1 (PAR-1) associated with tumor recurrence in localized adenocarcinoma (EA) of the esophagus treated with surgery alone.
  • : 4564 Background: Tumor angiogenesis is a well-recognized aspect of human cancer biology and is mediated at least in part by EGF and PAR-1, which in turn may impact the process of tumor growth and progression.
  • Systemic tumor recurrence after curative resection continues to be a significant problem in the management of patients with localized EA.
  • Further, it is being increasingly recognized that esophageal squamous cell carcinoma and EA are separate and distinct disease groups and need to be considered individually.
  • We therefore designed a large retrospective study of EA patients to identify novel molecular markers of prognosis to better define tumor stage and progression, and help to define novel targets, as well as surrogate-endpoints of disease progression and response to therapy.
  • METHODS: Between 1992 and 2005 normal esophageal tissue samples from 239 patients with localized EA treated with surgery alone were obtained at University of Southern California medical facilities.
  • 114 out of 239 (48%) patients had tumor recurrence, with a probability of 5-year recurrence of 0.62 ± 0.04.
  • RESULTS: PAR-1 -506 ins/del (p-value=0.003; log-rank test) and EGF +61 A>G (p-value=0.034; log-rank test) are adverse prognostic markers in univariate analysis.
  • CONCLUSIONS: This study supports the role of functional EGF and PAR-1 polymorphisms as independent prognostic markers in localized EA and may therefore help to identify patient subgroups at high risk for tumor recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963056.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Liu L Jr, Huang Y, Guo J, Wang ZH, Song DG: Correlation between FDG PET/CT and the expression of Ki-67, MMP-2, micro-vessel density (MVD), and pathological grading in squamous cell carcinoma of the esophagus. J Clin Oncol; 2009 May 20;27(15_suppl):e15556

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between FDG PET/CT and the expression of Ki-67, MMP-2, micro-vessel density (MVD), and pathological grading in squamous cell carcinoma of the esophagus.
  • : e15556 Background: Variable uptake of 18FDG has been noticed in positron emission tomography (PET) studies of patients with esophageal squamous cell carcinoma (ESCC).
  • The aim of the present study was to determine if <sup>18</sup>F-FDG PET/CT standardized uptake value (SUV) could quantitatively reflect tumor proliferation, invasion and angiogenesis, and to reveal the relationship between SUV and pathological grading of ESCC.
  • 18FDG uptake was semiquantitatively measured by SUV.Tumour sections were HE stained to determine the pathological grading,and were stained by immunohistochemistry for proliferation marker (Ki67), invasion marker (MMP-2), and angiogenic marker (CD34).
  • RESULTS: Among all the 47 cases,there were 13 well- differentiated squamous cell tumors, 16 moderately differentiated tumors and 18 poorly differentiated tumors,45 of 47 tumors revealed FDG. accumulation in primary tumor foci confirmed by subsequently histopathologically.
  • The mean SUV of well-differentiated, moderately differentiated and poorly differentiated tumors were 9.787±1.477, 12.313±0.479, 15.053±2.147 respectively, and a significant difference could be determined between them by statistical analysis(P=0.000).
  • SUV could reflect proliferation and invasion potential of tumor.
  • However, there is no significant correlation between SUV and MVD, thus it could not reflect tumor angiogenesis in ESCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962337.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Khushalani NI, Miecznikowski J, Wang D, Nowak N, Nava H, Nava ME, Tan W, Iyer R, Yang G, Pendyala L: Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): A phase II trial with gene expression profiling (GEP). J Clin Oncol; 2009 May 20;27(15_suppl):e15543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): A phase II trial with gene expression profiling (GEP).
  • Following our dose-finding phase I study, the present phase II neo-adjuvant (NA) EC trial was designed to examine the pCR rate using C, OXP and RT, with secondary end-points of evaluating toxicity, quality of life, and GEP of tumor tissue for correlation to therapeutic response.
  • GEP using Agilent microarrays was conducted on primary tumor tissue pre-treatment (Rx), day (D) 17 and at E; > 50% viable tumor cells were required.
  • 18 PTS have completed NA therapy; Grade 4 toxicity includes anemia (1), lymphopenia (2); grade 3 toxicity includes esophagitis (1), pneumonia (1), wound infection (1), anastomotic leak (2), esophageal fistula (1), bowel obstruction (1), fatigue (1), hyperbilirubinemia (1), elevated ALT, AST (1 & 2, respectively), hypoalbuminemia (3), OXP hypersensitivity (2) & leucopenia (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962302.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Lim EJ, Stella DL, Russell DM: Torrential upper gastrointestinal bleeding from 'downhill' oesophageal varices complicating long term central venous access for total parenteral nutrition. Frontline Gastroenterol; 2010 Jul;1(2):118-120

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Torrential upper gastrointestinal bleeding from 'downhill' oesophageal varices complicating long term central venous access for total parenteral nutrition.
  • Oesophageal varices usually develop in the setting of portal hypertension secondary to chronic liver disease.
  • However, superior vena cava (SVC) obstruction can result in 'downhill' varices forming in the upper oesophagus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Nephrol. 2008 Oct;12(5):407-15 [18401548.001]
  • [Cites] Dig Dis Sci. 1982 Jan;27(1):23-7 [6978238.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):1010-2 [18436214.001]
  • [Cites] Eur J Intern Med. 2006 Dec;17(8):586 [17142183.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1991 Nov;29(11):1484-8 [1663180.001]
  • [Cites] Neurology. 1996 Oct;47(4):1081-5 [8857750.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):1863, 2158 [19013160.001]
  • [Cites] Dis Chest. 1964 Dec;46:740-6 [14248507.001]
  • [Cites] Dtsch Med Wochenschr. 1998 May 29;123(22):691-5 [9645185.001]
  • (PMID = 28839559.001).
  • [ISSN] 2041-4137
  • [Journal-full-title] Frontline gastroenterology
  • [ISO-abbreviation] Frontline Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Somerville M, Pitt M: Surveillance of Barrett's oesophagus: do we yet know whether it is worthwhile? Frontline Gastroenterol; 2010 Jul;1(2):88-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance of Barrett's oesophagus: do we yet know whether it is worthwhile?
  • In 2004, the Peninsula Technology Assessment Group developed an economic model to assess the effectiveness and cost effectiveness of surveillance of Barrett's oesophagus in preventing morbidity and mortality from oesophageal adenocarcinoma.
  • At present, there seems little reason to change our original conclusion that surveillance of Barrett's oesophagus is unlikely to be cost effective and a definitive answer may only be possible from clinical trials now in progress.
  • As newer endoscopic techniques for treating Barrett's oesophagus and adenocarcinoma become more widely used, however, conventional surveillance programmes may no longer be undertaken, and revised economic models will be needed to assess the cost effectiveness of the new clinical pathways.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):868-79 [15476150.001]
  • [Cites] Histopathology. 2009 Jun;54(7):814-9 [19635100.001]
  • [Cites] Endoscopy. 2009 May;41(5):400-8 [19418393.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):501-7 [19410194.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):885-7; author reply 887 [15173278.001]
  • [Cites] Lancet. 2009 Mar 7;373(9666):850-61 [19269522.001]
  • [Cites] Am J Gastroenterol. 2008 Jun;103(6):1340-5 [18510606.001]
  • [Cites] Ann Intern Med. 2003 Feb 4;138(3):176-86 [12558356.001]
  • [Cites] Health Qual Life Outcomes. 2006 Nov 27;4:90 [17129380.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):588-99 [18272361.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jun;7(6):613-23 [19281858.001]
  • [Cites] Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv [16545207.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2043-53 [10445526.001]
  • [Cites] Pharmacoeconomics. 1998 Apr;13(4):397-409 [10178664.001]
  • [Cites] Am J Gastroenterol. 2008 May;103(5):1079-89 [18445097.001]
  • (PMID = 28839554.001).
  • [ISSN] 2041-4137
  • [Journal-full-title] Frontline gastroenterology
  • [ISO-abbreviation] Frontline Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


28. Ng T, DiPetrillo T, Suntharalingam M, Fontaine J, McNulty B, Akerman P, Chen W, Horiba MN, Burrows W, Safran H: Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: A phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: A phase II trial.
  • A phase II study was therefore initiated to evaluate the pathologic response rate of neoadjuvant PPX, cisplatin and radiation for patients with esophageal cancer.
  • METHODS: Eligible patients had pathologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or GE junction with no evidence of distant metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962301.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Batra U, Doval DC, Talwar V, Sharma JB, Sherali R: TIP regimen in metastatic or recurrent esophageal cancer: An Indian experience. J Clin Oncol; 2009 May 20;27(15_suppl):e15664

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TIP regimen in metastatic or recurrent esophageal cancer: An Indian experience.
  • : e15664 Background: Currently, there is no standard regimen for metastatic or recurrent upper or middle squamous cell esophageal cancer.
  • We therefore undertook this study to test the first-line combination of TIP regimen (Paclitaxel, Ifosfamide and cisplatinum) in patients with metastatic carcinoma of the esophagus.
  • METHODS: This study evaluated the efficacy, tolerability and toxicity profile of the TIP regimen in patients with metastatic or recurrent carcinoma of the upper or middle squamous cell carcinoma of esophagus.
  • The median time to tumor progression was 7 months and the median survival was 13 months (range 2-36 months).
  • CONCLUSIONS: The combination of Paclitaxel, Ifosfamide and Cisplatinum has significant activity in metastatic or recurrent esophageal cancer.
  • The ease of administration, cost effectiveness and suitable safety profile makes it an ideal first line regimen in metastatic esophageal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962761.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Braghetto I, Papapietro K, Csendes A, Gutierrez J, Fagalde P, Diaz E, Rodriguez A, Undurraga F: Nonesophageal side-effects after antireflux surgery plus acid-suppression duodenal diversion surgery in patients with long-segment Barrett's esophagus. Dis Esophagus; 2005 Aug 01;18(3):140-145

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonesophageal side-effects after antireflux surgery plus acid-suppression duodenal diversion surgery in patients with long-segment Barrett's esophagus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203867.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Pandurengan RK, Strom SS, Trent J 2nd: Gastrointestinal stromal tumor associated with other primaries: A study of 154 patients. J Clin Oncol; 2009 May 20;27(15_suppl):10567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor associated with other primaries: A study of 154 patients.
  • : 10567 Background: The objective of this study is to investigate the characteristics and survival rate of patients with Gastrointestinal Stromal Tumor (GIST) associated with other primary malignancies.
  • Multiple primaries included tumors that were not considered to be a metastasis, invasion or recurrence of GIST excluding non-melanoma skin cancer.
  • Data on gender, age at diagnosis of cancer, follow-up time after diagnosis, and death rate were collected.
  • Median age at diagnosis of GIST was 57 for patients with GIST only whereas it was 68 in patients with GIST+.
  • The total numbers of other primaries developed before the diagnosis of GIST was higher (134) than the primaries developed after the diagnosis of GIST (53).
  • The most frequent primaries observed before the diagnosis of GIST were prostate (25), breast (12), esophagus (9), kidney (7) and melanoma (6).
  • Lung (5) and kidney (5) were the most frequent type of primaries that developed after the diagnosis of GIST.
  • The 5-yr survival was 68% for patients with GIST+ when the other primary occurred before GIST, 61% for patients with GIST+ when the other primary occurred after the diagnosis of GIST, 58% for patients with GIST only, and 49% for GIST++ patients with two or more other primaries (p=0.002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963788.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Sharma K, Mohanti BK, Sharma DN, Rath GK, Julka PK, Muzumder S: Pattern of palliative care, pain management, and referral trends in developing countries: Still far from optimum. J Clin Oncol; 2009 May 20;27(15_suppl):e20694

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Maximum (60%) patients were of head and neck cancers followed by oesophagus (14%), lung (10%) and others.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Dvorak K, Fass R, Dekel R, Payne CM, Chavarria M, Dvorakova B, Bernstein H, Bernstein C, Garewal H: Esophageal acid exposure at pH ≤ 2 is more common in Barrett's esophagus patients and is associated with oxidative stress. Dis Esophagus; 2006 Oct 01;19(5):366-372

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal acid exposure at pH ≤ 2 is more common in Barrett's esophagus patients and is associated with oxidative stress.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203923.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. De Rezende L, Lucendo AJ, Álvarez-Argüelles H: Granular cell tumors of the esophagus: report of five cases and review of diagnostic and therapeutic techniques. Dis Esophagus; 2007 Oct 01;20(5):436-443

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumors of the esophagus: report of five cases and review of diagnostic and therapeutic techniques.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203918.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Tomas D, Tomić K, Bekavac-Bešlin M, Jukić Z, Belicza M, Krušlin B: Primary glomangioma of the esophagus mimicking esophageal papilloma. Dis Esophagus; 2006 Jun 01;19(3):208-211

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary glomangioma of the esophagus mimicking esophageal papilloma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203903.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Altorjay Á, Szilágyi A, Sárkány Á, Varga I, Jachymczyk G, Paál B, Kecskés G: Synchronous spontaneous perforation of the esophagus and a duodenal ulcer. Dis Esophagus; 2005 Aug 01;18(3):207-210

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous spontaneous perforation of the esophagus and a duodenal ulcer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203888.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Ernst S, Sanchez-Quintana D, Ho SY: Anatomy of the Pericardial Space and Mediastinum: Relevance to Epicardial Mapping and Ablation. Card Electrophysiol Clin; 2010 Mar;2(1):1-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Related to the fibrous pericardium overlying the posterior wall of the left atrium is the esophagus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Inc.
  • (PMID = 28770727.001).
  • [ISSN] 1877-9190
  • [Journal-full-title] Cardiac electrophysiology clinics
  • [ISO-abbreviation] Card Electrophysiol Clin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Agarwala AK, Hanna N, McCollum A, Bechar N, DiMaio M, Yu M, Tong Y, Becerra CR, Choy H: Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern. J Clin Oncol; 2009 May 20;27(15_suppl):4557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern.
  • : 4557 Background: Pre-operative chemoradiotherapy (CRT) followed by surgical resection is a standard treatment option for pts with resectable esophageal or GE junction (GEJ) carcinomas (CA).
  • We conducted this study to evaluate this regimen in pts with esophageal and GEJ CA.
  • METHODS: This is a single arm, open label pilot study combining cetuximab with XRT for pts with resectable esophageal and GEJ CA.
  • Key eligibility criteria are: squamous cell (SC)or adenoCA of the esophagus or GEJ, ECOG PS 0-2, clinical stage II -IVa, and eligible for esophagectomy.
  • RESULTS: Patient characteristics (n=40): median age 65 years (range, 54-82); 92% male; PS 0/1 63%/32%; esophageal/GEJ 65%/35%; adenoCA/SC 78%/22%; 36 pts have completed cetuximab and radiation and 26 pts have undergone esophagectomy.
  • CONCLUSIONS: Cetuximab and XRT results in pCR's in pts with esophageal and GEJ CA (rate of pCR 13/36), including patients with either SC or adenoCA histologies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963028.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Deschamps C, Wang K: Dear colleagues, readers and contributors to Diseases of the Esophagus. Dis Esophagus; 2007 Feb 01;20(1):1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dear colleagues, readers and contributors to Diseases of the Esophagus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28203914.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Feinstein TM, Agrawal S, Stoller RG, Egorin MJ, Argiris A: Phase I and pharmacokinetic (PK) study of dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 17 evaluable pts, there were no objective responses; 9 pts had stable disease: salivary gland cancer (3), thyroid (2), sarcoma (1), unknown primary (1), esophagus (1), and NSCLC (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961358.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. McAlindon ME, Sanders DS, Sidhu R: Capsule endoscopy: 10 years on and in the frontline. Frontline Gastroenterol; 2010 Jul;1(2):82-87

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The production of different capsule endoscopes to examine the oesophagus, small bowel and colon now means that almost all of the gut can be examined using this technology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2009 Jan;104(1):219-27 [19098872.001]
  • [Cites] Gastrointest Endosc. 2001 Feb;53(2):216-20 [11174299.001]
  • [Cites] Endoscopy. 2004 Dec;36(12):1054-9 [15578294.001]
  • [Cites] Scand J Gastroenterol. 2008;43(4):497-505 [18365916.001]
  • [Cites] Z Gastroenterol. 2009 Apr;47(4):339-46 [19358059.001]
  • [Cites] Endoscopy. 2006 Jan;38(1):42-8 [16429354.001]
  • [Cites] World J Gastroenterol. 2007 Aug 28;13(32):4372-8 [17708614.001]
  • [Cites] Endoscopy. 2009 Jul;41(7):618-37 [19588292.001]
  • [Cites] Endoscopy. 2008 May;40(5):414-21 [18302080.001]
  • [Cites] Endoscopy. 2009 Sep;41(9):762-6 [19662592.001]
  • [Cites] Endoscopy. 2007 Dec;39(12):1041-5 [18072053.001]
  • [Cites] Endoscopy. 2007 Jul;39(7):606-12 [17611915.001]
  • [Cites] Gastrointest Endosc. 2005 Jul;62(1):62-70 [15990821.001]
  • [Cites] Hepatology. 2008 May;47(5):1595-603 [18435461.001]
  • [Cites] Endoscopy. 2006 Jan;38(1):49-58 [16429355.001]
  • [Cites] Am J Gastroenterol. 2006 May;101(5):954-64 [16696781.001]
  • [Cites] Scand J Gastroenterol. 2006 Aug;41(8):983-8 [16803698.001]
  • [Cites] World J Gastroenterol. 2008 Jul 14;14(26):4137-41 [18636657.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 Aug;21(8):952-4 [19404201.001]
  • [Cites] Dig Liver Dis. 2006 Sep;38(9):696-8 [16920049.001]
  • [Cites] Endoscopy. 2007 Jul;39(7):613-5 [17516287.001]
  • [Cites] World J Gastroenterol. 2008 Mar 7;14(9):1313-7 [18322940.001]
  • [Cites] Med Bull (Ann Arbor). 1957 May;23(5):178-80 [13433948.001]
  • [Cites] Endoscopy. 2007 Mar;39(3):208-15 [17385105.001]
  • [Cites] Gastrointest Endosc. 2008 May;67(6):902-9 [18355824.001]
  • [Cites] Gastrointest Endosc. 2006 Apr;63(4):539-45 [16564850.001]
  • [Cites] Endoscopy. 2007 May;39(5):455-8 [17516353.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 May;6(5):536-44 [18242145.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):920-36 [18407270.001]
  • [Cites] J Clin Gastroenterol. 2006 Sep;40(8):688-91 [16940879.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):963-70 [17058158.001]
  • [Cites] Acta Radiol. 2006 Dec;47(10):1008-16 [17135001.001]
  • [Cites] Endoscopy. 2004 Jul;36(7):656-8 [15243892.001]
  • [Cites] Am J Gastroenterol. 2010 Jun;105(6):1240-8; quiz 1249 [20029412.001]
  • [Cites] Dig Liver Dis. 2007 Feb;39(2):140-5 [16965945.001]
  • [Cites] Am J Gastroenterol. 2005 Nov;100(11):2407-18 [16279893.001]
  • [Cites] World J Gastroenterol. 2008 Sep 14;14(34):5269-73 [18785278.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):525-32 [17459025.001]
  • [Cites] Gastrointest Endosc. 2008 Aug;68(2):267-72 [18378233.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):1047-53 [17058174.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jun;6(6):671-6 [18356113.001]
  • [Cites] Endoscopy. 2008 Apr;40(4):275-9 [18389444.001]
  • [Cites] Gut. 2003 May;52(5):742-6 [12692062.001]
  • [Cites] Clin Radiol. 2009 Apr;64(4):341-52 [19264177.001]
  • [Cites] Endoscopy. 2006 Apr;38(4):385-90 [16680639.001]
  • [Cites] Gut. 2008 Jan;57(1):125-36 [18094205.001]
  • [Cites] Dig Dis Sci. 2007 May;52(5):1382-6 [17357836.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):971-7 [17058159.001]
  • [Cites] Gastrointest Endosc. 2005 Jul;62(1):55-61 [15990820.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1624-31 [17459022.001]
  • [Cites] Gastrointest Endosc. 2009 Feb;69(2):253-9 [18640676.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Oct 1;22(7):595-604 [16181299.001]
  • [Cites] Radiology. 2008 Apr;247(1):64-79 [18372465.001]
  • [Cites] J Gastrointestin Liver Dis. 2009 Sep;18(3):273-8 [19795019.001]
  • [Cites] N Engl J Med. 2009 Jul 16;361(3):264-70 [19605831.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jun;6(6):661-70 [18550005.001]
  • [Cites] Gastroenterology. 2007 Nov;133(5):1697-717 [17983812.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1999 Jan;9(1):13-27 [9834314.001]
  • [Cites] World J Gastroenterol. 2009 Apr 28;15(16):1934-42 [19399924.001]
  • [Cites] Endoscopy. 2005 Oct;37(10 ):1051-4 [16189789.001]
  • [Cites] Nature. 2000 May 25;405(6785):417 [10839527.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):133-41 [15704047.001]
  • [Cites] Gastroenterology. 2004 Mar;126(3):643-53 [14988816.001]
  • (PMID = 28839553.001).
  • [ISSN] 2041-4137
  • [Journal-full-title] Frontline gastroenterology
  • [ISO-abbreviation] Frontline Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Cassier PA, Blesius AA, Perol D, Ray-Coquard I, Adenis A, Bui B, Bertucci F, Rios M, Le Cesne A, Blay J: Neoadjuvant imatinib in patients with locally advanced GIST in the prospective BFR14 trial. J Clin Oncol; 2009 May 20;27(15_suppl):10551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10551 Background: The role of surgery in the management of patients with advanced gastrointestinal stromal tumors (GIST) in the era of imatinib mesylate (IM) remains unknown.
  • We sought to assess the outcome of patients with locally advanced primary GIST tumors without metastases treated with IM in the neoadjuvant setting within the prospective BFR14 phase III trial.
  • Twenty patients were PS 0 or 1, primary tumor sites were: small intestine (n=7), peritoneum (n=7), rectum (n=4), stomach (n=4), esophagus (n=2), and pelvis (n=1).
  • Nine of the 25 patients underwent surgical resection of the primary tumor after a median of 7.3 (range 3.4-12.1) months of treatment with IM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963947.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Feilchenfeldt JW, Capanu M, Farooki A, Sully D, Miron B, Power DG, Jhawer M, Ilson DH, Kelsen DP, Shah MA: Diabetes mellitus (DM), serum glucose, and outcome in gastroesophageal (GE) cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15661

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their diagnosis is predictive of early recurrence following resection of colorectal cancer and of increased treatment related toxicity in localized breast cancer.
  • METHODS: 211 patients with GE cancer enrolled on 3 localized (2 esophagus, 1 gastric) and 4 metastatic consecutive prospective clinical trials (3 gastric, 1 esophagus) were examined.
  • Diagnosis of DM was based on clinical data, random glucose or fasting-glucose levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962769.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Boers JE, Meeuwissen H, Methorst N: HER2 status in 146 gastroesophageal carcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridisation methods (FISH and SISH). J Clin Oncol; 2009 May 20;27(15_suppl):e15555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15555 Background: In the industrialized world, the incidence of adenocarcinomas of the distal esophagus/gastric cardia is increasing rapidly and though the incidence of carcinomas of the gastric body / antrum are decreasing they still represent a significant health problem.
  • Several reports claim a significant HER2-positivity in gastro-esophageal adenocarcinomas.
  • METHODS: HER2 status was examined in gastro-esophageal carcinomas, comparing SP3 (Labvision) and 4B5 (Ventana) immunohistochemistry (IHC), conventional dual probe HER2 FISH (DAKO), and SISH (Ventana) in a single Dutch institution.
  • RESULTS: IHC was carried out on biopsies of 146 patients with adenocarcinomas of the esophagus (n=44), gastric cardia (n=28), body (n=24) and antrum (n=50).
  • Heterogenous HER2- positivity with partial staining/amplification was present in 73% of the adenocarcinomas, occasionally with only a tumor area of 10-20% showing positivity.
  • HER2-amplification was present in 27% of esophageal and 18% in gastric cardia carcinomas (resulting in 24% amplification of tumors of the esophago-gastric region).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962336.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Hohenberger P, Oladeji O, Licht T, Dimitrakopoulou-Strauss A, Jakob J, Pink D, Schwarzbach M, Ströbel P, Reichardt P, Wardelmann E: Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):10550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST).
  • : 10550 Background: We assessed the outcome of patients with locally advanced gastrointestinal stromal tumors (GIST) undergoing preoperative therapy with imatinib.
  • METHODS: 36 patients with biopsy proven GIST (23 f, 13 m, median age 58 (27-85) yrs, 31 primary tumors, 5 local recurrences) of the esophagus/EGJ (n=5), stomach (n=17), duodenum (n=2), small bowel (n=3), or rectum (n=9) were treated with imatinib 400mg/d for 6 mos. preop.
  • Average tumor size was 10.5 cm (4-28 cm).
  • According to Consensus two tumors were low risk, 11 intermediate, and 23 were high risk for aggressive behaviour.
  • 33 pts. completed the treatment schedule, two died from unrelated disease, another one had to be operated for tumor rupture.
  • Of the remaining 33, median tumor size shrank to 55 mm.
  • Complete tumor removal was possible in 28 pts without operative mortality, but two pts showed previously undetected peritoneal spread (R2 resection).
  • The extent of resection found 5 of 6 inoperable pts now resectable and in 21/25 pts a less extensive procedure could be performed in comparison to recommendations by previous tumor boards (segmental gastric resection for gastrectomy, avoidance of pancreatectomy, transanal resection instead of colo-anal anastomosis).
  • Substantial tumor shrinkage facilitates radical but conservative surgery and results in organ-preservation in the overwhelming majority of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Sekine I, Sumi M, Ito Y, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T: Phase I study of concurrent high-dose three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 26 patients were excluded because of V<sub>20</sub> > 30% (n=10), overdose to the esophagus (n=8) and brachial plexus (n=2), comorbidity (n=3), or patient refusal (n=3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963322.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Dennie T, Alberti D, Oliver K, LoConte N, Mulkerin D, Wilding G, Holen K, Fleming R, Bowen C, O'Neill V: A phase I study of capecitabine, oxaliplatin (CapOx), and lapatinib (L) in metastatic or advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2579

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of capecitabine, oxaliplatin (CapOx), and lapatinib (L) in metastatic or advanced solid tumors.
  • One pt had breast cancer and the remainder had non- colorectal GI malignancies (esophagus, hepatobiliary, and pancreas).
  • CONCLUSIONS: The regimen of CapOx and L has efficacy in the treatment of solid tumors with established responsiveness to fluoropyrimidines or Ox.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961891.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Kristeleit R, Calvert H, Arkenau H, Olmos D, Adam J, Plummer ER, Lock V, Squires M, Fazal L, Judson I: A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors.
  • Exposure of solid tumour cell lines to AT9283 in vitro induces an "aurora inhibitory" phenotype.
  • An additional 4 patients received at least six cycles of therapy (squamous cell carcinoma of the lung, adenocarcinoma of the esophagus and colorectal carcinoma [2]) with a best response of stable disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961883.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Capdevila J, Clive S, Tabernero J, Lardelli P, Soto-Matos A, Baselga J, Piera A, Pardos I, Rye R, Smyth JF: Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):2568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma.
  • PM00104 has shown broad in vitro and in vivo anti-tumor activity (IC<sub>50</sub> ≤ 10<sup>-8</sup> M) with an acceptable toxicology profile.
  • METHODS: The aim of this phase I study was to assess the safety profile, dose-limiting toxicities (DLT), maximum tolerated dose (MTD), recommended dose (RD), pharmacokinetics (PK), relationship between PK and pharmacodynamics (PD) and anti-tumor activity of PM00104 administered as a 24-hour i.v. infusion q3w.
  • Five pts developed DLTs: 2 pts at 5000 μg/m<sup>2</sup> (grade 4 thrombocytopenia/neutropenia and grade 3 nausea/vomiting in 1 pt; and grade 3 nausea in 1 pt); 1 at 4000 μg/m<sup>2</sup> (grade 4 neutropenia/thrombocytopenia and grade 3 asthenia); 1 at 3200 μg/m<sup>2</sup> (grade 3 tumor pain) and 1 at 266 μg/m<sup>2</sup> (grade 3 transaminase increase).
  • At the RD 6 more pts have been included in order to further evaluate the safety profile and anti-tumor activity.
  • No objective responses were seen but 3 pts with pancreatic adenocarcinoma, hepatocarcinoma and lower esophagus adenocarcinoma presented stable disease lasting >3 months.
  • CONCLUSIONS: PM00104 has shown an acceptable safety profile with signs of anti-tumor activity in pts with advanced malignancies when administered as a 24-hour i.v. infusion q3w.
  • PM00104 is also being evaluated with other administration schedules as monotherapy and in combination with other anti-tumor agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Wade FM, Pavlakis N, Receveur I, Leibman S, Smith GS: The role of cancer Nurse coordinator in foregut malignancy: Workload and costing considerations in the Australian setting. J Clin Oncol; 2009 May 20;27(15_suppl):e20559

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20559 Background: Foregut (esophageal and gastric) malignancy (FM) encompasses a number of diseases with poor outlook and complex and often morbid treatment.
  • Further, the CNC is pivotal in ensuring that benchmarks regarding intervals from diagnosis, to multidisciplinary assessment to treatment commencement are met.
  • The number of cancers arising from the esophagus or esophagogastric junction was 135 (62%), stomach 78 (36%) and small bowel 5 (2%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961033.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Badylak SF, Kochupura PV, Cohen IS, Doronin SV, Saltman AE, Gilbert TW, Kelly DJ, Ignotz RA, Gaudette GR: The Use of Extracellular Matrix as an Inductive Scaffold for the Partial Replacement of Functional Myocardium. Cell Transplant; 2006 Jan;15(1_suppl):29-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ECM scaffolds have been shown to support constructive remodeling of other tissue types including the lower urinary tract, the dermis, the esophagus, and dura mater by mechanisms that include the recruitment of bone marrow-derived progenitor cells, angiogenesis, and the generation of bioactive molecules that result from degradation of the ECM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863772.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Bioscaffold / Extracellular matrix / Myocardium / Regenerative medicine / Tissue engineering / Urinary bladder matrix
  •  go-up   go-down


52. Koh Y, Kim H, Lee H, Lee K, Oh D, Kim J, Im S, Kim T, Kim W, Bang Y: KIT and PDGFRAmutation status and their immunohistochemical (IHC) expression profile of gastrointestinal stromal tumor (GIST) patients treated with imatinib (IMT): Seven-year single-center experience. J Clin Oncol; 2009 May 20;27(15_suppl):10558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT and PDGFRAmutation status and their immunohistochemical (IHC) expression profile of gastrointestinal stromal tumor (GIST) patients treated with imatinib (IMT): Seven-year single-center experience.
  • Tumor DNA was extracted to investigate the mutation status of KITexon 9, exon 11, PDGFRA exon 12 and 18.
  • Location of primary disease included stomach (33), small bowel (34), rectum (10), esophagus (1), and omentum/mesentery (7).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963944.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Ruhstaller T, Pless M, Schuller JC, Kranzbühler H, von Moos R, Moosmann P, Rauch D, Montemurro M, Schneider PM, Hess V: Cetuximab in combination with chemoradiotherapy prior to surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase lb-ll trial of the Swiss Group for Clinical Cancer Research (SAKK 75/06). J Clin Oncol; 2009 May 20;27(15_suppl):4570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in combination with chemoradiotherapy prior to surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase lb-ll trial of the Swiss Group for Clinical Cancer Research (SAKK 75/06).
  • We investigated the safety and feasibility of adding cetuximab to neoadjuvant chemoradiation of locally advanced esophageal cancer.
  • METHODS: Pts with resectable, locally advanced squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the thoracic esophagus or gastroesophageal junction (staged by EUS, CT and PET scan) were treated with 2 cycles of induction chemotherapy (docetaxel 75mg/m2, cisplatin 75mg/m2 q3w and weekly cetuximab 250mg/m2), followed by concomitant chemo- immuno-radiation therapy (CIRT: docetaxel 20mg/m2, cisplatin 25mg/m2 and cetuximab 250mg/m2 weekly five times concomitant with 45 Gy radiotherapy in 25 fractions); followed by surgery 4-8 weeks later.
  • CONCLUSIONS: Adding cetuximab to preoperative chemoradiation for esophageal cancer is safe and feasible in a community-based multicenter setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963079.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. De Vita F, Orditura M, Innocente R, Vecchione L, Pinto C, Chiarion Sileni V, Martinelli E, Ruol A, Catalano G, Ciardiello F: A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC). J Clin Oncol; 2009 May 20;27(15_suppl):4546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC).
  • METHODS: Eligibility criteria: resectable, locally advanced (uT3 or uN1, T4 if deemed resectable) squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the esophagus; staged by EUS, CT and PET scan; age 18-70y; PS <2; normal organ functions.All pts received induction treatment with C at a starting dose of 400 mg/m<sup>2</sup> and further weekly infusion at a maintenance dose of 250 mg/m<sup>2</sup> and 4 cycles of FOLFOX-4 every two weeks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963011.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Bogoevski D, Schurr PG, Koenig AM, Busch P, Kutup A, Izbicki JR: Is there still place for endoscopic mucosal resection in patients with early oesophageal carcinomas? J Clin Oncol; 2009 May 20;27(15_suppl):e15640

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there still place for endoscopic mucosal resection in patients with early oesophageal carcinomas?
  • : e15640 Background: The objective of this study was to investigate whether limited resection of the oesophagogastric junction can be successfully used in the treatment of the patients with early oesophageal carcinomas.
  • METHODS: A total of 111 patients with early oesophageal cancer (57 adenocarcinomas, 54 squamous cell carcinomas) had surgical resection with systematic lymphadenectomy (41 thoracoabdominal-TA, 52 transhiatal-TH and 18 with limited resection of the oesophagogastric junction- LROGJ).
  • None of the 43 patients with high grade intraepithelial neoplasia (HGIEN) or oesophageal carcinoma limited to the mucosa had lymphatic spread, as compared with 15 of 68 (22.1%) with affection of the submucosa.
  • Multifocal neoplasia was detected in three patients with SCC HGIEN (30%) but not in AC HGIEN!
  • Nine out of 44 (20.4%) patients with early SCC had multifocal neoplasia, compared to 6 out of 53 (11.3%) patients in AC (p=0.322).
  • The sensitivity of the preoperative tumour dept staging (endoscopic ultra sound - EUS; and CT) was astonishing low (only 50% for cT1b), as was the specificity (66.7% for cT1a and only 87.5% for cT1b).
  • On multivariate analysis, only histological tumor type (AC) was independent predictor of survival.
  • CONCLUSIONS: Considering the limitations and pitfalls of endoscopic and classical resectional procedures, the quest for alternative and "patient tailored" treatment in patients with early oesophageal carcinoma carries on.
  • A valuable alternative can be the limited resection of the oesophago-gastric junction under sparing of the healthy oesophagus and stomach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962740.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Kelsen D, Jhawer M, Ilson D, Tse A, Randazzo J, Robinson E, Capanu M, Shah MA: Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial. J Clin Oncol; 2009 May 20;27(15_suppl):4512

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The addition of BEV to chemotherapy has improved survival in several solid tumors, and has demonstrated encouraging activity in GE cancer (Shah et al, JCO 2006).
  • RESULTS: Pt enrollment has completed: median age 57(range 29-74), median KPS 80% (70-100), M:F 32:12, gastric/GEJ/esophagus 22:17:5.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962705.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Bjerregaard JK, Schønnemann KR, Jensen HA, Vestermark LW, Hansen TP, Pfeiffer P: Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Localisation of primary was: Esophagus 10%, GE junction 64%, gastric 26%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962695.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Jhawer M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah MA, MET111643 Investigators and GlaxoSmithKline: Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts with distal esophagus, GE junction or stomach adenocarcinoma, 0-2 prior chemotherapy regimens, adequate organ function, measurable disease, and ECOG PS 0-2 are sequentially enrolled in 2 cohorts:.
  • Pre- and on-treatment tumor biopsies in select pts and plasma samples in all pts are analyzed for GSK089 effects on direct and downstream drug targets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962690.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Fetterly GJ, Brady WE, LeVea CM, Litwin AM, Zagst PD, Prey JD, Tarquini M, Giardina MK, Iyer RV, Khushalani NI: A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC). J Clin Oncol; 2009 May 20;27(15_suppl):e15540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: AGC (esophagus, gastric, hepatocellular) patients (pts) with adequate organ function, performance status (ECOG 0-1), and 0-1 prior chemotherapy regimens are eligible for this phase 1 study to determine the MTD of V.
  • Tumor biopsy pre-Rx and at D13 are being done for TGFβ and survivin expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962309.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Iwase H, Shimada M, Tsuzuki T, Hirashima N, Goto H: Concurrent chemoradiotherapy for locally advanced cervical esophageal carcinoma: A phase II study of oral fluoropyrimidine agents (UFT, S-1) plus cisplatin with radiotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):6043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy for locally advanced cervical esophageal carcinoma: A phase II study of oral fluoropyrimidine agents (UFT, S-1) plus cisplatin with radiotherapy.
  • : 6043 Background: Carcinoma of the cervical esophagus is a highly virulent disease.
  • We evaluated concurrent chemoradiotherapy using an oral fluoropyrimidine (UFT, S-1) and cisplatin in patients with locally advanced cervical esophageal carcinoma.
  • Four patients had stage II tumors and 16 had stage III tumors.
  • Complete response (CR) was attained in all 4 patients with stage II tumors.
  • CONCLUSIONS: Chemoradiotherapy with an oral fluoropyrimidine (UFT, S-1) plus cisplatin is convenient, tolerable, and effective, and it is a promising nonsurgical management option for patients with locally advanced cervical esophageal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961907.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Li J, Omo A, Liu L, Liu L, Tang Y, Pan T: Huge benign mesenchymoma in pharynx-esophagus. Ann Thorac Surg; 2006 Jun;81(6):2283-5
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge benign mesenchymoma in pharynx-esophagus.
  • Benign mesenchymoma is an uncommon neoplastic disease and its occurrence in pharynx-esophagus is even more rarely reported.
  • The origin of this tumor was in the pharynx-esophagus, and complete excision was achieved through a laterocervical approach.
  • [MeSH-major] Esophageal Neoplasms / pathology. Mesenchymoma / pathology. Pharyngeal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731171.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


62. Boran C, Sengul N, Balaban YH, Gürel S: Multinodular leiomyoma of the esophagus with internodular hydropic degeneration and bulbous serosal protrusions similar to cotyledonoid uterine leiomyoma. Dis Esophagus; 2007;20(2):187-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multinodular leiomyoma of the esophagus with internodular hydropic degeneration and bulbous serosal protrusions similar to cotyledonoid uterine leiomyoma.
  • Leiomyoma is the most common benign tumor of the esophagus, and usually occurs as a solitary mass.
  • We report a case of esophageal leiomyoma which shows multinodular growth pattern with bulbous serosal protrusions.
  • The patient was a 26-year-old woman who had an esophageal ulcerated mass near the gastroesophageal junction.
  • Based on the clinical diagnosis, total gastrectomy with distal esophagectomy was performed.

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17439606.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Reid BJ: Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark; 2010;9(1-6):307-24
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early events during neoplastic progression in Barrett's esophagus.
  • Barrett's esophagus is a condition in which the stratified squamous epithelium of the distal esophagus is replaced by specialized intestinal metaplasia.
  • Clinical management of Barrett's esophagus, like many other "premalignant" conditions, is characterized by overdiagnosis of benign early changes that will not cause death or suffering during the lifetime of an individual and underdiagnosis of life-threatening early disease.
  • Neoplastic progression unfolds in space and time, and Barrett's esophagus provides one of the best models for rapid advances, including "gold standard" cohort studies, to distinguish individuals who do and do not progress to cancer.
  • A large body of evidence accumulated over several decades implicates chromosome instability in neoplastic progression from Barrett's esophagus to esophageal adenocarcinoma.
  • Small, spatial scale studies have been used to infer the temporal order in which genomic abnormalities develop during neoplastic progression in Barrett's esophagus.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1186-96 [17287898.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694 [17338734.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1914-21 [17236199.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):532-42 [17330261.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G264-70 [17431220.001]
  • [Cites] J Mol Med (Berl). 2007 Jul;85(7):733-43 [17415542.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] N Engl J Med. 1992 Mar 12;326(11):737-40 [1445507.001]
  • [Cites] Gastroenterol Clin North Am. 1991 Dec;20(4):791-816 [1787014.001]
  • [Cites] Hum Pathol. 1992 May;23(5):479-82 [1568744.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2946-50 [1581911.001]
  • [Cites] Gastroenterol Clin Biol. 1991;15(10):703-10 [1816011.001]
  • [Cites] Gut. 1992 May;33(5):587-91 [1351861.001]
  • [Cites] Gut. 1992 Jun;33(6):733-7 [1624150.001]
  • [Cites] Gastroenterology. 1992 Dec;103(6):1769-76 [1360434.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1322-7 [8443812.001]
  • [Cites] Endoscopy. 1993 Nov;25(9):648-51 [8119224.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2292-5 [8162566.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1589-95 [8194706.001]
  • [Cites] Stat Med. 1994 May 15;13(9):955-68 [8047747.001]
  • [Cites] Gut. 1994 Oct;35(10):1348-51 [7959183.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):151-5 [7816807.001]
  • [Cites] Br J Surg. 1994 Dec;81(12):1766-8 [7827934.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1994;59:577-83 [7587115.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 [12552134.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] Ann Thorac Surg. 2001 Aug;72(2):334-9; discussion 339-41 [11515862.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Am J Gastroenterol. 2001 Sep;96(9):2575-83 [11569678.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8284-9 [11719461.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):682-8 [11726842.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):121-8 [11896567.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9433-8 [12093899.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1179-86 [12439111.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16226-31 [12446840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16910-5 [12486240.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Jun;18(6):683-9 [12753151.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] Gut. 2003 Aug;52(8):1081-4 [12865262.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4211-7 [12874028.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):695-701 [12951588.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Am J Pathol. 1988 Apr;131(1):53-61 [3354644.001]
  • [Cites] Gastroenterology. 1989 Feb;96(2 Pt 1):355-67 [2910757.001]
  • [Cites] Lab Invest. 1989 Jan;60(1):65-71 [2911184.001]
  • [Cites] Lab Invest. 1989 Mar;60(3):418-32 [2927081.001]
  • [Cites] Stat Med. 1989 Apr;8(4):431-40 [2727467.001]
  • [Cites] Gastroenterology. 1989 Oct;97(4):815-20 [2777038.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):885-7; author reply 887 [15173278.001]
  • [Cites] J Pathol. 2004 Jul;203(3):780-8 [15221937.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6332-40 [17452981.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2649-55 [18086770.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):111-7 [18199717.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Feb 15;27(4):316-20 [18062791.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1303-10 [18000824.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] PLoS One. 2008;3(4):e1890 [18382671.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4163-72 [18519675.001]
  • [Cites] Dig Liver Dis. 2008 Jul;40(7):510-22 [18400571.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1128-35 [18602665.001]
  • [Cites] Genome Res. 2008 Sep;18(9):1518-29 [18577705.001]
  • [Cites] Science. 2008 Sep 5;321(5894):1280-1 [18772403.001]
  • [Cites] Gut. 2008 Oct;57(10):1354-9 [18424568.001]
  • [Cites] Int J Cancer. 2008 Nov 15;123(10):2331-6 [18729198.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Dis Esophagus. 2008;21(6):529-38 [18840137.001]
  • [Cites] Mol Cancer. 2008;7:75 [18831746.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1392-1413, 1413.e1-5 [18801365.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6988-95 [18980994.001]
  • [Cites] PLoS One. 2008;3(11):e3809 [19043591.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):413-23 [19138988.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):178-86 [19151715.001]
  • [Cites] Cell Cycle. 2009 Mar 15;8(6):809-17 [19229128.001]
  • [Cites] Cancer Biomark. 2009;5(3):143-58 [19407369.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3305-14 [19417022.001]
  • [Cites] Gastrointest Endosc. 1999 Dec;50(6):814-8 [10570342.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2087-95 [10601379.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):555-66 [10666385.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1702-10 [10815888.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Genome Res. 2000 Aug;10(8):1126-37 [10958631.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] BMJ. 2000 Nov 18;321(7271):1252-5 [11082084.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3164-70 [11306503.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Dec;38(4):302-6 [14566848.001]
  • [Cites] Mod Pathol. 2004 May;17(5):588-96 [15017433.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3414-27 [15150093.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Gut. 2006 Jun;55(6):764-74 [16368780.001]
  • [Cites] Oncogene. 2006 May 18;25(21):3084-92 [16407829.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1935-40 [17035402.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6637-42 [17121882.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):509-16 [16537709.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Oct 15;42(2):281-6 [2790761.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] Surg Oncol. 1995 Jun;4(3):163-71 [7582189.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):259-63 [8542577.001]
  • [Cites] Oncogene. 1996 May 2;12(9):1873-8 [8649847.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Gut. 2003 May;52(5):623-8 [12692043.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1116-9 [8630885.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4499-502 [8813147.001]
  • [Cites] Am J Clin Pathol. 1996 Sep;106(3):298-304 [8816585.001]
  • [Cites] Gut. 1996 Jul;39(1):5-8 [8881798.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1867-73 [8934532.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):586-91 [9128304.001]
  • [Cites] Surg Oncol Clin N Am. 1997 Jul;6(3):515-31 [9210354.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2133-7 [9329980.001]
  • [Cites] Oncogene. 1997 Oct 2;15(14):1653-9 [9349498.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):641-51 [9708926.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):950-7 [9764589.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Oct 1;106(1):11-7 [9772903.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] JAMA. 1998 Nov 25;280(20):1747-51 [9842949.001]
  • [Cites] Cytometry. 1998 Dec 15;34(6):257-63 [9879642.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Nat Genet. 1999 May;22(1):106-9 [10319873.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):23-6 [10385717.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1862-7 [10430093.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4784-7 [10519384.001]
  • [Cites] Surgery. 1957 Jun;41(6):881-94 [13442856.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):51-60 [15613288.001]
  • [Cites] Cancer Lett. 2005 Jan 20;217(2):221-30 [15617840.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):751-60 [15720801.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):775-83 [15784018.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):830-4 [15824152.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3146-54 [15833844.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):584-91 [15825175.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1274-81 [16230080.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] J Pathol. 2006 Jan;208(1):100-7 [16278815.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2616-21 [16393209.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):1931-9 [14499768.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6293-300 [17975140.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Dec;26(11-12):1465-77 [17900269.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1106-13 [17932229.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7629-33 [15492292.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Gastroenterology. 1978 Oct;75(4):683-7 [710836.001]
  • [Cites] Arch Surg. 1983 May;118(5):543-9 [6838359.001]
  • [Cites] Gastroenterology. 1987 Jul;93(1):1-11 [3582897.001]
  • [Cites] Am J Gastroenterol. 1987 Oct;82(10):1012-5 [3661507.001]
  • [Cites] Gastroenterology. 1988 Jan;94(1):81-90 [3335302.001]
  • (PMID = 22112482.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA091955; United States / NCI NIH HHS / CA / P01CA91955
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS578448; NLM/ PMC4026269
  •  go-up   go-down


64. Liu CH, Chang HC, Goan YG: Large pedunculated lipoma of the esophagus. J Formos Med Assoc; 2008 May;107(5):424-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large pedunculated lipoma of the esophagus.
  • Pedunculated lipoma of the esophagus is rare and easily misdiagnosed in clinical practice.
  • The presenting symptoms of esophageal lipoma are dysphagia, regurgitated mass and persistent sensation of a lump in the throat.
  • The most frequent location of the tumor pedicle is the upper esophageal sphincter.
  • Although the lipoma is pathologically benign, if it is large enough, it may cause airway obstruction secondary to the mechanical pressure to the larynx when the tumor is regurgitated.
  • Esophagography and chest computed tomography revealed that he might have an esophageal submucosal or intraluminal tumor mass.
  • Panendoscopy showed a pedunculated tumor mass within the esophageal lumen with its peduncle arising from the cervical esophagus.
  • The tumor mass measured 9.0 x 4.7 x 2.5 cm in size.
  • Pathology showed a lipoma arising from the submucosa of the esophagus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492628.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


65. Lee SY, Chan WH, Sivanandan R, Lim DT, Wong WK: Recurrent giant fibrovascular polyp of the esophagus. World J Gastroenterol; 2009 Aug 7;15(29):3697-700
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent giant fibrovascular polyp of the esophagus.
  • Giant fibrovascular polyps of the esophagus and hypopharynx are rare benign esophageal tumors.
  • They arise most commonly in the upper esophagus and may, rarely, originate in the hypopharynx.
  • Even though they are benign, they may be lethal due to either bleeding or, rarely, asphyxiation if a large polyp is regurgitated.
  • The polyps may not be well visualized on endoscopy and imaging plays a vital role in aiding diagnosis as well as providing important information for pre-operative planning, such as the location of the pedicle, the vascularity of the polyp and the tissue elements of the mass.
  • We review the recent literature and report a case of a 61-year-old man with a recurrent giant esophageal fibrovascular polyp with illustrative contrast barium swallow, CT and intra-operative images, who required several surgeries via a combination of endoscopic, trans-oral, trans-cervical, trans-thoracic and trans-abdominal approaches.
  • [MeSH-major] Esophageal Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Polyps / surgery
  • [MeSH-minor] Esophagus / pathology. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Esophagus. 2000;13(4):324-7 [11284984.001]
  • [Cites] Yonsei Med J. 2001 Apr;42(2):264-6 [11371118.001]
  • [Cites] Dig Dis Sci. 2002 Nov;47(11):2598-604 [12452402.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):485-7 [12683881.001]
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):781-7 [8610549.001]
  • [Cites] Eur Radiol. 1998;8(2):264-9 [9477279.001]
  • [Cites] Am J Otolaryngol. 2007 Mar-Apr;28(2):115-7 [17362817.001]
  • [Cites] Abdom Imaging. 2005 Nov-Dec;30(6):653-5 [16132431.001]
  • [Cites] Ann Thorac Surg. 2006 Jan;81(1):393-6 [16368421.001]
  • [Cites] Eur Radiol. 2006 Mar;16(3):764-6 [16470418.001]
  • [Cites] Arch Pathol Lab Med. 2006 May;130(5):725-7 [16683893.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):749-51 [16891825.001]
  • [Cites] Abdom Imaging. 1999 Mar-Apr;24(2):109-10 [10024391.001]
  • (PMID = 19653354.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 13
  • [Other-IDs] NLM/ PMC2721250
  •  go-up   go-down


66. Solerio D, Gasparri G, Ruffini E, Camandona M, De Angelis C, Raggio E, Dei Poli M: Giant fibrovascular polyp of the esophagus. Dis Esophagus; 2005;18(6):410-2
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant fibrovascular polyp of the esophagus.
  • Giant fibrovascular polyps are uncommon benign esophageal tumors almost always originating from the cervical esophagus, frequently from the upper esophageal sphincter.
  • Only fiberoptic endoscopy suggested the correct diagnosis because the mass fluctuated endoluminally with the spasm of vomiting.
  • A giant fibrovascular polyp was observed and excised.
  • If a malignant or benign extensive intramural tumor had been identified, a total esophagectomy would have been performed.
  • In our opinion the possibility of the presence of a fibrovascular polyp should always be considered in the presence of an undetermined esophageal mass, and in these cases a left cervical incision is the preferred surgical access.
  • Once the correct diagnosis is established, a major esophageal resection should always be avoided.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16336614.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Prenzel KL, Schäfer E, Stippel D, Beckurts KT, Hölscher AH: Multiple giant leiomyomas of the esophagus and stomach. Dis Esophagus; 2006;19(6):504-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple giant leiomyomas of the esophagus and stomach.
  • Leiomyomas are rare esophageal disorders, although among the benign esophageal neoplasms, they are the most common.
  • Multiple leiomyomas are distinguished from esophageal leiomyomatosis, an extremely rare condition, which is associated with Alport syndrome, showing deletions and rearrangements of the COL4A5/COL4A6 gene.
  • On endoscopy multiple nodules covered with intact mucosa were present, the largest tumor arising from the gastro-esophageal border infiltrating the cardia.
  • Barium swallow demonstrated narrowing of the middle and lower esophagus with the upper third of the stomach filled by the tumor.
  • Thorax and abdominal CT scans revealed infiltration of almost the total aboral esophagus by the tumor with compression of left and right bronchi.
  • Due to the extended tumor growth with infiltration of the upper third of the stomach, a total esophago-gastrectomy with reconstruction by colon interposition was performed.
  • On histopathological examination multiple esophageal leiomyomas with infiltration of the proximal third of the stomach was shown.
  • Immunohistochemically the tumor stained positive for desmin and sm-actin and negative for CD34 and c-kit.
  • In young patients with diffuse multinodular infiltration by encapsulated tumors, esophageal leiomyomatosis should be considered.
  • If the proximal third of the stomach is infiltrated by the tumor an extended resection is necessary.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069596.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / COL4A5 protein, human; 0 / Collagen Type IV
  •  go-up   go-down


68. Kim TS, Song SY, Han J, Shim YM, Jeong HS: Giant fibrovascular polyp of the esophagus: CT findings. Abdom Imaging; 2005 Nov-Dec;30(6):653-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant fibrovascular polyp of the esophagus: CT findings.
  • Giant fibrovascular polyp of the esophagus is a rare intraluminal benign tumor that is covered with normal esophageal mucosa, which consists of fibrous tissue, adipose tissue, and vascular structures.
  • We report a case of a giant fibrovascular polyp of the esophagus in which feeding vessels were well visualized within the stalk of the mass at contrast-enhanced helical computed tomography.
  • [MeSH-major] Esophageal Neoplasms / radiography. Polyps / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132431.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Hamvas B, Szilágyi A, Orosz Z, Altorjay A: [Giant solitary fibrovascular polyp of the esophagus causing diagnostic problems]. Magy Seb; 2006 Apr;59(2):129-32
MedlinePlus Health Information. consumer health - Esophagus Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant solitary fibrovascular polyp of the esophagus causing diagnostic problems].
  • The giant fibrovascular polyp is a rear benign entity of the esophagus.
  • The authors present a case of a patient with a giant fibrovascular polyp caused serious diagnostic problems.
  • The preoperative examination confirmed a 60x50x90 mm size tumor-like intramural lesion in the upper third of the esophagus.
  • During the operation we found a sessile intraluminal polyp which has removed.
  • The histology confirmed giant fibrovascular polyp.
  • [MeSH-major] Esophageal Diseases / diagnosis. Esophageal Diseases / surgery. Polyps / diagnosis. Polyps / surgery
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784037.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


70. Asteriou C, Konstantinou D, Lalountas M, Kleontas A, Setzis K, Zafiriou G, Barbetakis N: Nine years experience in surgical approach of leiomyomatosis of esophagus. World J Surg Oncol; 2009;7:102
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nine years experience in surgical approach of leiomyomatosis of esophagus.
  • BACKGROUND: Leiomyomas of esophagus, although rare, are the most frequent benign tumors of esophagus.
  • Aim of this study is the presentation of 7 patients with esophageal leiomyomas who underwent surgical treatment during a 9-year period.
  • METHODS: Epidemiological data (sex, age), the presenting symptoms, diagnostic examinations, tumor location, histopathological findings and the safety and efficacy of surgical resection are analyzed and assessed.
  • In 3 cases the tumor was located at the lower esophagus, while in the other 4 cases, the leiomyoma was found at the median third of esophagus.
  • None of them received resection of part of the esophagus.
  • The mean diameter of the resected tumors was 4.3 cm.
  • CONCLUSIONS: Esophageal leiomyoma is a benign tumor, which causes symptoms only if its size becomes large.
  • [MeSH-major] Esophageal Neoplasms / surgery. Leiomyomatosis / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2000 Jan;46(1):88-92 [10601061.001]
  • [Cites] Virchows Arch. 2001 Jan;438(1):1-12 [11213830.001]
  • [Cites] Gastrointest Endosc. 2002 Jan;55(1):44-9 [11756913.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2002 Apr 10;82(7):456-8 [12133514.001]
  • [Cites] Scand J Gastroenterol. 2002 Jul;37(7):856-62 [12190103.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2007 Apr;13(2):78-81 [17505413.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2002 Jul;24(4):394-6 [12408774.001]
  • [Cites] J Am Coll Surg. 1995 Sep;181(3):257-62 [7670685.001]
  • [Cites] Radiology. 1996 May;199(2):533-6 [8668807.001]
  • [Cites] Ann Thorac Surg. 2005 Apr;79(4):1122-5 [15797036.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4 Suppl):S43-8 [12297748.001]
  • (PMID = 20030817.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2804581
  •  go-up   go-down


71. Sargent RL, Hood IC: Asphyxiation caused by giant fibrovascular polyp of the esophagus. Arch Pathol Lab Med; 2006 May;130(5):725-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asphyxiation caused by giant fibrovascular polyp of the esophagus.
  • Giant fibrovascular polyps of the esophagus are rare, benign, "tumorlike" lesions that typically present as large pedunculated growths arising in the cervical esophagus.
  • Diagnosis is best made by upper endoscopic evaluation; surgical excision is the definitive treatment.
  • We describe a case of asphyxiation caused by laryngeal occlusion by a giant esophageal polyp and we provide a review of the literature.
  • [MeSH-major] Airway Obstruction / etiology. Asphyxia / etiology. Esophageal Neoplasms / complications. Polyps / complications
  • [MeSH-minor] Biomarkers, Tumor / analysis. Fatal Outcome. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Choking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683893.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


72. Yoshino T, Habu Y: A case of endoscopically resected fibrovascular polyp arose from lower esophagus. Clin J Gastroenterol; 2008 Oct;1(3):97-99

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of endoscopically resected fibrovascular polyp arose from lower esophagus.
  • Fibrovascular polyps are very rare benign tumors almost originating from the cervical esophagus.
  • The barium esophagogram showed a smooth and rounded polypoid tumor at EG junction.
  • Endoscopy revealed the smooth and white polypoid tumor at EG junction, which arose from the lower esophagus, and the head of the tumor was herniated into the stomach.
  • Because the potentially malignant tumor was suspected by endoscopic biopsy, and the tumor was small in size, we performed endoscopic resection.
  • The final diagnosis was the fibrovascular polyp of the esophagus.
  • This is a very rare case, because this polyp was not only small but also arose from lower esophagus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 1999 Jun;31(5):401-4 [10433053.001]
  • [Cites] Dis Esophagus. 2000;13(4):324-7 [11284984.001]
  • [Cites] Dig Dis Sci. 2002 Nov;47(11):2598-604 [12452402.001]
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):781-7 [8610549.001]
  • (PMID = 26193645.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Endoscopy / Esophagus / Fibrovascular polyp
  •  go-up   go-down


73. Lopes J, Hochwald SN, Lancia N, Dixon LR, Ben-David K: Autoimmune esophagitis: IgG4-related tumors of the esophagus. J Gastrointest Surg; 2010 Jun;14(6):1031-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune esophagitis: IgG4-related tumors of the esophagus.
  • We present a case of a 23-year-old gentleman who presented with dysphagia, weight loss, and recurrent esophageal strictures requiring multiple dilatations.
  • An endoscopic ultrasound with esophagogastroduodenoscopy revealed a mass present in the distal esophagus.
  • Fine needle aspiration suggested that the mass in the lower esophagus resembled a gastrointestinal stromal tumor.
  • After surgical resection, final pathologic analysis revealed that the tumor was comprised of benign-appearing fibroinflammatory cells with an increase and predominance of IgG4-positive plasma cells.
  • The microscopic appearance was consistent with a benign condition as a result of an IgG4-related process.
  • We present the pre-operative imaging, operative management, pathologic diagnosis, and literature review of this rare condition and the first known report of autoimmune esophagitis as part of the IgG4 spectrum of diseases.
  • [MeSH-major] Autoimmune Diseases / pathology. Esophagitis / pathology. Esophagus / pathology. Plasma Cells / pathology

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20195914.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G
  • [Number-of-references] 14
  •  go-up   go-down


74. Garrido E, Marín E, González C, Juzgado D, Boixeda D, Vázquez-Sequeiros E: [Endoscopic mucosal resection of Abrikosoff's tumor of the esophagus]. Gastroenterol Hepatol; 2008 Nov;31(9):572-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic mucosal resection of Abrikosoff's tumor of the esophagus].
  • [Transliterated title] Mucosectomía endoscópica de un tumor de Abrikosoff esofágico.
  • Abrikosoff's tumor (AT), or granular cell tumor (GCT), is relatively rare in the gastrointestinal tract, where the most common site is the esophagus.
  • This tumor is usually found incidentally when an upper gastrointestinal endoscopy is carried out for another reason.
  • The definitive diagnosis is histological.
  • The origin of GCT is neurogenic and the tumor is composed of eosinophilic granular cytoplasm and PAS-positive cells, which show the S-100 protein on immunohistochemistry.
  • Although GCT is usually clinically and histologically benign, some malignant cases have been reported.
  • Consensus is lacking on the treatment and follow-up of this tumor.
  • Currently, endoscopic mucosal resection is a safe and effective technique to treat submucosal esophageal lesions, allowing subsequent histologic analysis.
  • We present three patients with esophageal CGT, who were definitively treated with endoscopic mucosal resection.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagoscopy. Granular Cell Tumor / surgery
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Humans. Male. Middle Aged. Neoplasm Proteins / analysis. S100 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19091245.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


75. K C S, Kouzu T, Hishikawa E: Multiple granular cell tumor of the esophagus treated endoscopically. JNMA J Nepal Med Assoc; 2007 Jan-Mar;46(165):40-3
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple granular cell tumor of the esophagus treated endoscopically.
  • Granular cell tumor (GCT) of esophagus is a rare lesion, usually found incidentally during upper gastrointestinal endoscopic examination undertaken for another reasons.
  • The origin of this neoplasm is still unclear but no organ seems to be immune to this neoplasm.
  • Although most of the lesions are benign, few reports of malignant GCT, synchronous as well as metachronous, are also reported.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721562.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


76. Solbakken AM, Hovde Ø, Glomsaker T: [The use of stents in benign oesophageal conditions]. Tidsskr Nor Laegeforen; 2005 Aug 25;125(16):2175-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of stents in benign oesophageal conditions].
  • [Transliterated title] Bruk av stent ved benigne tilstander i oesophagus.
  • BACKGROUND: In recent years, self-expanding stents have been used to treat benign perforations and strictures of the oesophagus.
  • METHODS: We conducted a PubMed search of literature from January 1st 1993 to February 7th 2005 on the use of self-expanding stents in benign oesophageal conditions.
  • RESULTS: Only case reports and minor series are published in the literature; further studies are needed in order to define the future role of stents in benign disease.
  • Present experience indicates that self-expanding metal stents can be used in benign perforations of the oesophagus, provided that the stent is removed once the perforation has healed.
  • When stents are used in benign strictures, a high number of complications should be expected; the literature is more ambiguous as to whether or not this procedure should be recommended.
  • [MeSH-major] Esophageal Perforation / therapy. Esophageal Stenosis / therapy. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16138129.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Metals; 0 / Plastics
  • [Number-of-references] 81
  •  go-up   go-down


77. Kong J, Stairs DB, Lynch JP: Modelling Barrett's oesophagus. Biochem Soc Trans; 2010 Apr;38(2):321-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modelling Barrett's oesophagus.
  • Barrett's oesophagus is the replacement of normal squamous oesophageal epithelium with an intestinalized columnar epithelium.
  • Although some insight has been gained as to what Barrett's oesophagus is, how this columnar epithelium emerges from within a stratified squamous epithelium remains an unanswered question.
  • We have sought to determine whether oesophageal keratinocytes can be trans-differentiated into Barrett's oesophagus cells.
  • Using an Affymetrix microarray, we found unexpectedly that gene-expression patterns in the Barrett's oesophagus were only slightly more similar to the normal small intestine than they were to the normal oesophagus.
  • Thus gene-expression patterns suggest significant molecular similarities remain between Barrett's oesophagus cells and normal squamous oesophageal epithelium, despite their histological resemblance with intestine.
  • Retroviral-mediated Cdx2 (Caudal-type homeobox 2) expression in immortalized human oesophageal keratinocytes engineered with human telomerase reverse transcriptase (EPC2-hTERT cells) could be established transiently, but not maintained, and was associated with a reduction in cell proliferation.
  • However, when combined with treatments that induce chromatin remodelling, there was a significant induction of Barrett's oesophagus-associated genes.
  • Studies are ongoing to determine whether other intestinal transcription factors, either alone or in combination, can provoke greater intestinalization of oesophageal keratinocytes.
  • We conclude that, on the basis of gene-expression patterns, Barrett's oesophagus epithelial cells may represent an intermediate between oesophageal keratinocytes and intestinal epithelial cells.
  • Moreover, our findings suggest that it may be possible to induce Barrett's oesophagus epithelial cells from oesophageal keratinocytes by altering the expression of certain critical genes.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298176.001).
  • [ISSN] 1470-8752
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK068366; United States / NCI NIH HHS / CA / CA138998; United States / NCI NIH HHS / CA / P01 CA098101; United States / NIDDK NIH HHS / DK / P30-DK50306
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 50
  •  go-up   go-down


78. Li H, Hu B, Li T, Jin M, Hao J: A rare case of giant solitary fibrous tumor of the esophagus. Ann Thorac Surg; 2009 Dec;88(6):2019-21
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of giant solitary fibrous tumor of the esophagus.
  • Giant solitary fibrous tumor of the esophagus is a very rare neoplasm.
  • We herein report a successful surgically treated solitary fibrous tumor of the esophagus.
  • The preoperative diagnostic workup, including a computed tomographic chest scan, endoscopy, endoscopic ultrasonography, and barium swallow, demonstrated a giant pedunculated intraluminal mass in the esophagus.
  • The tumor was completely resected through a transthoracic esophagotomy, combined with an intraoperative endoscopy.
  • A microscopic examination and immunohistochemical studies supported the diagnosis of a benign solitary fibrous tumors of the esophagus.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Solitary Fibrous Tumors / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Endoscopy, Gastrointestinal. Endosonography. Follow-Up Studies. Humans. Male. Middle Aged. Radiography, Thoracic. Thoracotomy / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19932285.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


79. Chella B, Nosotti M, Baisi A, Lattuada E, Mazzone A, Santambrogio L: Unusual presentation of a transparietal cavernous hemangioma of the esophagus. Dis Esophagus; 2005;18(5):349-54
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of a transparietal cavernous hemangioma of the esophagus.
  • Hemangiomas are tumors of vascular origin and represent less than 3% of benign neoplasm of the esophagus.
  • A malignancy could not be excluded by a complete work-up, including esophagogram, endoscopic biopsies, CT scan, esophageal endoscopic ultrasonography, PET and thoracoscopic biopsies.
  • Only after partial esophagectomy with laparoscopic gastric mobilization was histological diagnosis obtained.
  • In fact, on microscopic observation of the specimen, the neoplasm appeared to be a cavernous hemangioma of the esophageal submucosa with transparietal extension.

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197539.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Ba-Ssalamah A, Zacherl J, Noebauer-Huhmann IM, Uffmann M, Matzek WK, Pinker K, Herold C, Schima W: Dedicated multi-detector CT of the esophagus: spectrum of diseases. Abdom Imaging; 2009 Jan-Feb;34(1):3-18
MedlinePlus Health Information. consumer health - Esophagus Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedicated multi-detector CT of the esophagus: spectrum of diseases.
  • Its ability to cover a large volume in a very short scan time, and in a single breath hold with thin collimation and isotropic voxels, allows the imaging of the entire esophagus with high-quality multiplanar reformation and 3D reconstruction.
  • Proper distention of the esophagus and stomach (by oral administration of effervescent granules and water) and optimally timed administration of intravenous contrast material are required to detect and characterize disease.
  • In contrast to endoscopy and double-contrast studies of the upper GI tract, CT provides information about both the esophageal wall and the extramural extent of disease.
  • Preoperative staging of esophageal carcinoma appears to be the main indication for MDCT.
  • In addition, MDCT allows detection of other esophageal malignancies, such as lymphoma and benign esophageal tumors, such as leiomyma.
  • A diagnosis of rupture or fistula of the esophagus can be firmly established using MDCT.
  • Furthermore, miscellaneous esophageal conditions, such as achalasia, esophagitis, diverticula, and varices, are incidental findings and can also be visualized with hydro-multi-detector CT.
  • Multi-detector CT is a valuable tool for the evaluation of esophageal wall disease and serves as an adjunct to endoscopy.
  • [MeSH-major] Esophageal Diseases / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Contrast Media. Esophageal Neoplasms / pathology. Esophageal Neoplasms / radiography. Humans. Imaging, Three-Dimensional. Neoplasm Staging. Radiographic Image Interpretation, Computer-Assisted

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653787.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 43
  •  go-up   go-down


81. Obszynska JA, Atherfold PA, Nanji M, Glancy D, Santander S, Graham TA, Otto WR, West K, Harrison RF, Jankowski JA: Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo. Gut; 2010 Feb;59(2):156-63
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo.
  • BACKGROUND: Barrett's oesophagus is a common premalignant lesion caused partly by acid reflux.
  • Although the requisite therapy, proton pump inhibitors (PPIs), have been implicated in the progression of Barrett's oesophagus in animal models, harmful effects of prolonged PPI therapy in Barrett's oesophagus is both inconclusive and controversial.
  • RESULTS: Gastrin and its cognate receptor CCK(2)R were expressed highest in the stomach, then less in Barrett's oesophagus and least in squamous oesophagus (SqE) (n=20 paired t-test, p<0.01).
  • Analysis of the change in Barrett's oesophagus segment length change in 70 patients who were randomised to high or low PPI dose showed no difference over 2 years (n=70 t-test, p=0.8).
  • In vitro gastrin also induced changes in OE33(E)(cckr) Barrett's oesophagus cells, but not OE21(E)(cckr) squamous cells, transfected with CCK(2)R; migration was induced by 1 ng/ml of gastrin but proliferation only increased with 100 ng/ml (paired t-test, p<0.01) and both were abolished by antagonists.
  • CONCLUSION: While the short-term effects of gastrin enhance epithelial restitution in Barrett's oesophagus (but not squamous mucosa) there is no clinical evidence that Barrett's oesophagus length expands over time.
  • This study, which is the largest and longest term randomised controlled trial of gastrin biology in Barrett's oesophagus, is further proof of the clinical safety of PPI therapy.
  • [MeSH-major] Barrett Esophagus / drug therapy. Esophageal Neoplasms / drug therapy. Gastrins / biosynthesis. Precancerous Conditions / drug therapy. Proton Pump Inhibitors / therapeutic use
  • [MeSH-minor] Adult. Aged. Cell Movement / drug effects. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Enzyme-Linked Immunosorbent Assay / methods. Esophagus / metabolism. Female. Gastric Mucosa / metabolism. Gene Expression. Humans. Male. Middle Aged. RNA, Messenger / genetics. Receptor, Cholecystokinin B / biosynthesis. Receptor, Cholecystokinin B / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gut. 2010 Aug;59(8):1157-8; authr reply 1158 [20639256.001]
  • [CommentIn] Gut. 2010 Feb;59(2):148-9 [20176635.001]
  • (PMID = 19651631.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gastrins; 0 / Proton Pump Inhibitors; 0 / RNA, Messenger; 0 / Receptor, Cholecystokinin B
  •  go-up   go-down


82. Harikumar R, Simikumar, Aravindan SK, Thomas V: Abrikosoff's tumor of the esophagus: case report and review of literature. Trop Gastroenterol; 2006 Jan-Mar;27(1):52-3
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abrikosoff's tumor of the esophagus: case report and review of literature.
  • Abrikosoff's tumor or granular cell tumor is a neoplasm of neural origin, usually located in the head and neck region.
  • A majority of these neoplasms are benign.
  • Only 4-6% of granular cell tumors are located in the gastrointestinal tract.
  • It is extremely unusual for these tumors to be located in the esophagus.
  • [MeSH-major] Esophageal Neoplasms / pathology. Granular Cell Tumor / pathology
  • [MeSH-minor] Adult. Esophageal and Gastric Varices / complications. Gastroesophageal Reflux / etiology. Humans. Liver Cirrhosis, Alcoholic / complications. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910065.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 13
  •  go-up   go-down


83. Bann S, Moorthy K, Shaul T, Foley R: Laparoscopic transhiatal surgery of the esophagus. JSLS; 2005 Oct-Dec;9(4):376-81
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic transhiatal surgery of the esophagus.
  • Patients with tumors of the esophagus and high-grade dysplasia in a Barrett's esophagus were included.
  • Seventeen transhiatal resections were completed, 2 were converted to open procedures, and 1 transhiatal resection of a benign tumor was performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1997 Jul;122(1):8-14 [9225908.001]
  • [Cites] Int Surg. 1997 Jan-Mar;82(1):1-4 [9189787.001]
  • [Cites] World J Surg. 1997 Oct;21(8):822-31 [9327673.001]
  • [Cites] Int Surg. 1997 Apr-Jun;82(2):109-12 [9331833.001]
  • [Cites] Surg Clin North Am. 1997 Oct;77(5):1169-96 [9347836.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):218-23 [10064749.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):293-7 [10064770.001]
  • [Cites] J Am Coll Surg. 2000 Mar;190(3):372-8 [10703866.001]
  • [Cites] Arch Surg. 2000 Aug;135(8):920-5 [10922253.001]
  • [Cites] Ann Thorac Surg. 2000 Aug;70(2):418-22 [10969655.001]
  • [Cites] Ann Thorac Surg. 2000 Sep;70(3):906-11; discussion 911-2 [11016332.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):338-44 [11224620.001]
  • [Cites] Surg Endosc. 2001 Feb;15(2):176-82 [11285963.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Surg Endosc. 2003 Mar;17(3):515-9 [12399847.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):486-94; discussion 494-5 [14530720.001]
  • [Cites] Adv Surg. 1993;26:397-410 [8418572.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Feb;105(2):265-76; discussion 276-7 [8429654.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):320-1 [8472139.001]
  • [Cites] Am J Surg. 1993 Apr;165(4):390-8 [8480870.001]
  • [Cites] Ann Surg. 1993 Jul;218(1):97-104 [8328835.001]
  • [Cites] Ann Thorac Surg. 1993 Sep;56(3):667-70 [8379767.001]
  • [Cites] Ann Thorac Surg. 1993 Sep;56(3):675-9 [8379769.001]
  • [Cites] Ann Thorac Surg. 1993 Sep;56(3):721-30 [8379780.001]
  • [Cites] Br J Surg. 1994 Feb;81(2):236-8 [8156345.001]
  • [Cites] Endosc Surg Allied Technol. 1994 Feb;2(1):21-5 [8081911.001]
  • [Cites] Endosc Surg Allied Technol. 1994 Feb;2(1):26-31 [7521764.001]
  • [Cites] World J Surg. 1994 May-Jun;18(3):339-46 [8091773.001]
  • [Cites] World J Surg. 1995 Sep-Oct;19(5):745-7 [7571674.001]
  • [Cites] Br J Surg. 1996 Apr;83(4):540-2 [8665254.001]
  • [Cites] Br J Surg. 1996 May;83(5):675-8 [8689217.001]
  • [Cites] Surg Endosc. 1996 Feb;10(2):147-51 [8932617.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Dec;112(6):1533-40; discussion 1540-1 [8975845.001]
  • [Cites] Aust N Z J Surg. 1997 Feb-Mar;67(2-3):131-2 [9068556.001]
  • [Cites] Aust N Z J Surg. 1997 Feb-Mar;67(2-3):148-9 [9068563.001]
  • [Cites] Arch Surg. 1997 Sep;132(9):943-7; discussion 947-9 [9301605.001]
  • (PMID = 16381348.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3015642
  •  go-up   go-down


84. Huang Q, Hardie LJ: Biomarkers in Barrett's oesophagus. Biochem Soc Trans; 2010 Apr;38(2):343-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers in Barrett's oesophagus.
  • Biomarkers are needed to screen multiple stages in the clinical pathway of Barrett's oesophagus patients; from disease diagnosis to risk stratification and predicting response to therapy.
  • The majority of Barrett's oesophagus patients remain undiagnosed in the general population.
  • In order to develop a tool to screen for Barrett's oesophagus in the primary care setting, minimally invasive sampling methods coupled with immunocytology-based biomarkers are currently being assessed.
  • Biomarkers are also being developed to improve detection of high-grade dysplasia and oesophageal adenocarcinoma, utilizing brush cytology combined with FISH (fluorescence in situ hybridization), and to assess therapeutic success and risk of complication during photodynamic therapy.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / genetics. Biomarkers / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298180.001).
  • [ISSN] 1470-8752
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C11347
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Pharmacological
  • [Number-of-references] 50
  •  go-up   go-down


85. Shaheen NJ, Richter JE: Barrett's oesophagus. Lancet; 2009 Mar 7;373(9666):850-61
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's oesophagus.
  • Barrett's oesophagus is a metaplastic change of the lining of the oesophagus, such that the normal squamous epithelium is replaced by specialised or intestinalised columnar epithelium.
  • The disorder seems to be a complication of chronic gastro-oesophageal reflux disease, although asymptomatic individuals might also be affected, and it is a risk factor for the development of oesophageal adenocarcinoma, a cancer with rapidly increasing incidence in developed societies.
  • We discuss the molecular changes necessary for the development of Barrett's oesophagus and its progression to cancer, and new strides in both the endoscopic detection of the lesion and the treatment of dysplastic disease.
  • Also, we assess the effectiveness of efforts to screen patients at risk of Barrett's oesophagus, and whether such efforts avert cancer death.
  • We conclude with a discussion of future directions for research, focusing on treatment of early neoplasia, and modifications of current practices to show our evolving understanding of this condition.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus. Esophageal Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269522.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 139
  •  go-up   go-down


86. Perçinel S, Savaş B, Yilmaz G, Erinanç H, Küpana Ayva S, Bektaş M, Ensari A: Granular cell tumor of the esophagus: three case reports and review of the literature. Turk J Gastroenterol; 2008 Sep;19(3):184-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the esophagus: three case reports and review of the literature.
  • The esophagus is the most common site of origin of gastrointestinal tract granular cell tumors.
  • Approximately 270 cases of esophageal granular cell tumors have been reported in the literature.
  • Most esophageal granular cell tumors are found incidentally during endoscopy.
  • Although granular cell tumor of the esophagus has become easily recognizable by its endoscopic features, it has to be differentiated from other benign and malignant mucosal and submucosal lesions.
  • The majority of esophageal granular cell tumors are asymptomatic and benign; thus, close follow-up of the patients with endoscopy could be considered sufficient as a therapeutic management.
  • Three cases of granular cell tumors with complaints of epigastric discomfort, regurgitation, nausea, and vomiting, which were detected in the lower part of the esophagus on upper gastrointestinal tract endoscopy, are discussed with the most recent literature review on this subject.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Granular Cell Tumor / diagnosis
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Esophagoscopy. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115155.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 53
  •  go-up   go-down


87. Bonino JA, Sharma P: Barrett's esophagus. Curr Opin Gastroenterol; 2006 Jul;22(4):406-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus.
  • PURPOSE OF REVIEW: Barrett's esophagus continues to be a popular topic among clinicians and researchers alike.
  • Population based studies have finally been undertaken to better identify subset populations at high risk of developing Barrett's esophagus, and possible better tolerated alternatives to standard endoscopy for cost-effective screening.
  • In addition, several studies over the past year have marked a transition from identifying those with Barrett's esophagus and in need of intensive surveillance, to an increasing number of novel treatment therapies that are now primed to move from experimental protocols to clinical practice.
  • RECENT FINDINGS: Obesity's role as a risk factor for the development of Barrett's esophagus continues to be better defined.
  • Various disorders affecting the motility of the gastrointestinal tract, such as celiac sprue and scleroderma, and their relationship with Barrett's esophagus development are becoming more widely recognized.
  • The use of endoscopic mucosal resection and photodynamic therapy for treatment of dysplastic Barrett's esophagus continues to gain increased acceptance, with an additional wealth of supportive data for its effectiveness becoming available.
  • SUMMARY: The past year has brought many advances in the epidemiology and endoscopic treatment of those with Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus. Endoscopy, Gastrointestinal / methods. Esophagectomy / methods. Mass Screening / methods. Photochemotherapy / methods

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760758.001).
  • [ISSN] 0267-1379
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


88. Binderup MD, Jensen VJ, Busch S: [Lymphangioma of the oesophagus]. Ugeskr Laeger; 2009 Jan 26;171(5):312-3
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphangioma of the oesophagus].
  • Lymphangiomas are benign tumours that rarely occur in the oesophagus.
  • A sessile, 5-mm polyp was seen at gastroscopy.
  • [MeSH-major] Esophageal Neoplasms / pathology. Lymphangioma / pathology

  • Genetic Alliance. consumer health - Lymphangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19176159.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


89. Bird-Lieberman EL, Fitzgerald RC: Barrett's esophagus. Gastroenterol Clin North Am; 2008 Dec;37(4):921-42, x
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus.
  • Barrett's esophagus is an important step in the pathway to esophageal adenocarcinoma.
  • Since most patients with Barrett's esophagus are undiagnosed and patients present with advanced adenocarcinoma de novo, prognosis for this disease remains poor.
  • To identify those people with Barrett's esophagus who are at particular risk many new technologies are being developed.
  • [MeSH-major] Barrett Esophagus

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028325.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ MC/ U105365007; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 131
  •  go-up   go-down


90. Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY: Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol; 2005 Aug;124(2):282-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.
  • Overexpression of decoy receptor (DcR) 3 protein, a recently discovered member of the tumor necrosis factor receptor superfamily, was examined in 40 esophagogastrectomy specimens containing areas of Barrett esophagus (n = 27), low-grade dysplasia (n = 27), high-grade dysplasia or carcinoma in situ (n = 22), and esophageal adenocarcinoma (EAC; n = 28) with immunohistochemical analysis.
  • The results revealed significantly more overexpression of DcR3 in high-grade dysplasia or carcinoma in situ and EAC than in benign esophageal mucosa (both P < .0001), Barrett esophagus (both P < .001), and low-grade dysplasia (P < .01 and P = .033, respectively).
  • Low-grade dysplasia also showed significant overexpression of DcR3 compared with benign esophagus (P < .05) but not with Barrett esophagus (P > .05).
  • Our results suggest that overexpression of DcR3 protein might aid in the diagnosis of high-grade dysplasia or carcinoma in situ and EAC and also might serve as a potential therapeutic target.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Esophageal Neoplasms / metabolism. Membrane Glycoproteins / biosynthesis. Precancerous Conditions / metabolism. Receptors, Cell Surface / biosynthesis. Receptors, Tumor Necrosis Factor / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Receptors, Tumor Necrosis Factor, Member 6b. Up-Regulation

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16040301.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface; 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human
  •  go-up   go-down


91. De Rezende L, Lucendo AJ, Alvarez-Argüelles H: Granular cell tumors of the esophagus: report of five cases and review of diagnostic and therapeutic techniques. Dis Esophagus; 2007;20(5):436-43
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumors of the esophagus: report of five cases and review of diagnostic and therapeutic techniques.
  • Granular cell tumors (GCT) of the esophagus are stromal lesions originating from the Schwann cells of the submucosal neuronal plexus.
  • Although they are very infrequent, they constitute the second largest cause of non-epithelial tumors in the esophagus after leiomyomas.
  • These tumors are generally benign, although a certain number of malignant, aggressive cases have been reported.
  • Diagnosis requires that this possibility be ruled out before deciding on which course of therapeutic action to take as well as familiarization with the relevant indicators.
  • GCT linked synchronically or metachronically to other malignant neoplasias of the esophagus have also been described, but the actual extent of this association is uncertain.
  • All of these were benign and were treated conservatively.
  • The article discusses new aspects relating to the diagnosis of these lesions and the role carried out by endoscopic ultrasonography in their characterization, both at preliminary diagnosis and monitoring levels.
  • Endoscopic therapeutic techniques are analyzed (resection with forceps or diathermy handles, yttrium-aluminum-garnet laser ablation, alcohol injection) in esophageal GCT, which have overtaken surgery in most cases due to their efficiency, greater safety and fewer complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760659.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins
  • [Number-of-references] 30
  •  go-up   go-down


92. Palanivelu C, Rangarajan M, John SJ, Annapoorni S, Senthilkumar S: A rare cause of intermittent dysphagia: giant fibrovascular polyp of the proximal esophagus. J Coll Physicians Surg Pak; 2007 Jan;17(1):51-2
MedlinePlus Health Information. consumer health - Swallowing Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare cause of intermittent dysphagia: giant fibrovascular polyp of the proximal esophagus.
  • Fibrovascular polyps account for only 0.5-1% of all benign esophageal tumors and causes intermittent dysphagia.
  • Investigations revealed a submucosal tumor of the proximal esophagus causing luminal compromise.
  • [MeSH-major] Deglutition Disorders / etiology. Esophageal Diseases / complications. Polyps / complications

  • Genetic Alliance. consumer health - Dysphagia.
  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204222.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


93. Blacha MM, Sloots CE, Van Munster IP, Wobbes T: Dysphagia caused by a fibrovascular polyp: a case report. Cases J; 2008;1(1):334
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysphagia caused by a fibrovascular polyp: a case report.
  • Barium contrast study of the esophagus and esophagoscopy demonstrated a fibrovascular polyp.
  • This, almost 10 cm benign esophageal tumor, was removed surgically by a cervical esophagotomy.
  • A fibrovascular polyp is a rare benign tumor of the esophagus, which, however, may give serious complications as asphyxia resulting from laryngeal obstruction leading to sudden death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Sep;18(9):1005-9 [16894315.001]
  • [Cites] Arch Pathol Lab Med. 2006 May;130(5):725-7 [16683893.001]
  • [Cites] Ann Thorac Surg. 2005 Oct;80(4):1196-201 [16181840.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Nov-Dec;20(10):1979-82 [10588130.001]
  • [Cites] J Gastroenterol. 2004 Dec;39(12):1205-9 [15622487.001]
  • [Cites] Abdom Imaging. 1999 Mar-Apr;24(2):109-10 [10024391.001]
  • [Cites] Dig Dis Sci. 2002 Nov;47(11):2598-604 [12452402.001]
  • [Cites] Am J Forensic Med Pathol. 2005 Sep;26(3):275-81 [16121086.001]
  • (PMID = 19019249.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2602996
  •  go-up   go-down


94. Kauer WK, Stein HJ, Dittler HJ, Siewert JR: [Barrett's esophagus]. Chirurg; 2005 Mar;76(3):258-62
MedlinePlus Health Information. consumer health - GERD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Barrett's esophagus].
  • [Transliterated title] Barrett-Osophagus Verhältnis zwischen Ausmass der intestinalen Metaplasie, Funktion des unteren Osophagussphinkters und Säure- bzw. Gallereflux.
  • INTRODUCTION: It is widely accepted that long segments of Barrett's esophagus are caused by end-stage gastroesophageal reflux disease (GERD), but little is known about the correlation of severity of GERD and extent of metaplasia.
  • METHODS: Twenty normal volunteers and 142 patients with different extent of intestinal metaplasia (39 with intestinal metaplasia limited to the esophagogastric junction, 48 with short segments of Barrett's esophagus, and 55 with long segments) underwent manometry and combined pH-bilirubin monitoring.
  • RESULTS: The extent of intestinal metaplasia correlated to the exposition of gastric and duodenal juice in the esophagus and inversely with a competent lower esophageal sphincter.
  • [MeSH-major] Barrett Esophagus / diagnosis. Bilirubin / analysis. Duodenogastric Reflux / complications. Esophagogastric Junction / pathology. Esophagogastric Junction / physiopathology. Esophagus / pathology. Gastric Acidity Determination. Gastroesophageal Reflux / complications. Manometry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / pathology. Esophageal Neoplasms / physiopathology. Female. Humans. Male. Metaplasia. Middle Aged. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Precancerous Conditions / physiopathology. Risk Factors. Statistics as Topic

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1990 Oct;108(4):769-77; discussion 777-8 [2218890.001]
  • [Cites] Ann Surg. 1992 Jul;216(1):35-43 [1632700.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Mar;117(3):572-80 [10047662.001]
  • [Cites] Thorax. 1961 Mar;16:36-41 [13712529.001]
  • [Cites] Arch Surg. 2001 Nov;136(11):1267-73 [11695971.001]
  • [Cites] J Gastrointest Surg. 1998 Nov-Dec;2(6):547-53; discussion 553-4 [10457313.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1930-6 [12190156.001]
  • [Cites] J Gastrointest Surg. 1997 Mar-Apr;1(2):113-22 [9834337.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):522-30; discussion 530-2 [9351720.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Jan;105(1):107-11 [8419690.001]
  • [Cites] Ann Med. 1999 Feb;31(1):46-50 [10219713.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):98-103; discussion 103-4 [7818006.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1007-10 [11490786.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):525-31; discussion 531-3 [7574932.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):633-9 [9516382.001]
  • [Cites] Arch Surg. 1983 May;118(5):543-9 [6838359.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):344-51 [10716147.001]
  • [Cites] Am J Gastroenterol. 2002 Mar;97(3):554-60 [11922546.001]
  • [Cites] Surg Endosc. 2003 Jan;17(1):43-8 [12364989.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Jul;9(3):270-8 [9263345.001]
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):91-5 [8836727.001]
  • [Cites] Gastroenterology. 1996 Nov;111(5):1192-9 [8898632.001]
  • [Cites] Surgery. 1995 Jun;117(6):699-704 [7778033.001]
  • (PMID = 15580449.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


95. Kammori M, Izumiyama N, Nakamura K, Kurabayashi R, Kashio M, Aida J, Poon SS, Kaminishi M: Telomere metabolism and diagnostic demonstration of telomere measurement in the human esophagus for distinguishing benign from malignant tissue by tissue quantitative fluorescence in situ hybridization. Oncology; 2006;71(5-6):430-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere metabolism and diagnostic demonstration of telomere measurement in the human esophagus for distinguishing benign from malignant tissue by tissue quantitative fluorescence in situ hybridization.
  • OBJECTIVE: We have developed a novel method for evaluating telomere length in four different cell types in non-cancerous and cancerous mucosal tissue from 15 cases of squamous cell carcinoma of the esophagus using tissue quantitative fluorescence in situ hybridization (Q-FISH).
  • We hypothesized that the very rapid cell proliferation observed in esophageal squamous cell carcinomas might accelerate the telomere shortening and chromosomal instability associated with carcinogenesis.
  • METHODS: Tissue Q-FISH and the telomere to centromere intensity ratio (TCR) were used to compare telomere shortening in tissue sections taken from esophageal squamous cell carcinomas and adjacent non-cancerous esophageal tissues.
  • RESULTS: The peak percentage of TCR was <1 for esophageal squamous carcinoma cells and >1 for the non-cancerous esophageal cell types.
  • CONCLUSION: These results suggest the presence of stem cells in the basal layer of the esophagus.
  • Esophageal squamous cell carcinomas also display anaphase bridges, evidencing chromosomal instability.
  • In conclusion, our TCR method can be used to distinguish between benign and malignant tissue in esophageal lesions.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Esophageal Neoplasms / diagnosis. Esophagus / pathology. In Situ Hybridization, Fluorescence / methods. Telomere / genetics
  • [MeSH-minor] Aged. Anaphase / genetics. Biomarkers, Tumor / biosynthesis. Centromere / pathology. Chromosomal Instability / genetics. Humans. Male. Middle Aged. Stem Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17878747.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


96. Bonino JA, Sharma P: Barrett's esophagus. Curr Opin Gastroenterol; 2005 Jul;21(4):461-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus.
  • PURPOSE OF REVIEW: Significant advances have been made over the past year to identify individuals with Barrett's esophagus, who are at increased risk of malignant transformation.
  • We summarize some of the important advances in that regard including: improved understanding in areas of epidemiology of those with Barrett's esophagus, identification of the pathways responsible for dysplastic and metaplastic development, selection of patient populations who would most benefit from surveillance protocols, and identification of biomarkers signifying progression of metaplastic changes.
  • RECENT FINDINGS: Barrett's esophagus is being better recognized in patients presenting with extra-esophageal symptoms of gastroesophageal reflux such as chronic cough and asthma.
  • Recent reports from some surgical series further suggest the importance of gastric and even duodenal reflux in the etiology of esophageal metaplastic development.
  • There appears to be a select group of individuals with familial predilection for the development of Barrett's esophagus.
  • Retrospective studies continue to show apparent survival benefit in individuals with Barrett's esophagus undergoing surveillance endoscopy.
  • Endoscopic ablative therapy may provide clinicians an attractive alternative to surgical resection in individuals with high-grade esophageal dysplasia and early adenocarcinoma.
  • SUMMARY: The past year has brought many advances in the epidemiology, pathogenesis, surveillance, and treatment of those with Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus. Precancerous Conditions
  • [MeSH-minor] Adenocarcinoma / pathology. Disease Progression. Esophageal Neoplasms / pathology. Humans. Intestinal Mucosa / pathology. Metaplasia / pathology. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15930989.001).
  • [ISSN] 0267-1379
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


97. Padula A, Chin NW, Azeez S, Resetkova E, Andriko JA, Miettinen M: Primary gastrointestinal stromal tumor of the esophagus in an HIV-positive patient. Ann Diagn Pathol; 2005 Feb;9(1):49-53
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal stromal tumor of the esophagus in an HIV-positive patient.
  • We describe a rare case of malignant gastrointestinal stromal tumor (GIST) of the esophagus presenting in an HIV-positive man.
  • Not only did the tumor arise from an unusual anatomic site for GIST, namely, the esophagus, but it also had a predominant epithelioid cell morphology that is uncommon and preferentially associated with aggressive behavior.
  • This immunophenotype corresponded to that of stromal tumors arising in the more common sites like stomach and small intestine as well as to that of a reported series of esophageal GISTs in the general population.
  • Mutations of the c-kit protein was detected in the tumor, confirming previous observations.
  • This further documents that esophageal GIST and the more common benign esophageal spindle cell lesions are pathologically distinct entities and despite its rarity, esophageal GIST should be recognized by pathologists and clinicians.
  • The occurrence of this tumor in an HIV-positive patient is coincidental, and it resulted in an extremely unusual metastatic site that has not been reported for GISTs.
  • [MeSH-major] Esophageal Neoplasms / pathology. Gastrointestinal Stromal Tumors / pathology. HIV Infections / pathology. Neoplasms, Complex and Mixed / secondary
  • [MeSH-minor] Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Endosonography. Epithelioid Cells / chemistry. Epithelioid Cells / pathology. Humans. Immunoenzyme Techniques. Male. Middle Aged. Proto-Oncogene Proteins c-kit / analysis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692952.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


98. Dilemmas in managing Barrett's oesophagus. Drug Ther Bull; 2006 Sep;44(9):69-72
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dilemmas in managing Barrett's oesophagus.
  • In the UK, oesophageal adenocarcinoma accounts for over 7,000 deaths per year and its incidence is rising.
  • One risk factor for this cancer is Barrett's oesophagus.
  • Of people with Barrett's oesophagus, about 1% per year develop adenocarcinoma, around 30-125 times the rate in the general population.
  • So it has been suggested that people with reflux should be screened for Barrett's oesophagus, and those with the condition should be kept under surveillance to detect dysplasia or adenocarcinoma in the early stages.
  • Here we discuss the problems in managing patients with Barrett's oesophagus.
  • [MeSH-major] Barrett Esophagus / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009567.001).
  • [ISSN] 0012-6543
  • [Journal-full-title] Drug and therapeutics bulletin
  • [ISO-abbreviation] Drug Ther Bull
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; R16CO5Y76E / Aspirin
  • [Number-of-references] 72
  •  go-up   go-down


99. Hongo M: [Preface: Recent perspectives of the Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1319-22
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preface: Recent perspectives of the Barrett's esophagus].
  • As the prevalence of reflux esophagitis is increasing in Japan, due to increased amount of energy intake and improved hygiene with the reduced H. pylori infection, the number of patients having Barrett's esophagus is also increasing.
  • In the Western countries, adenocarcinoma of the esophagus is rapidly increasing among the white elder male, where the reflux esophagitis is more common.
  • Terminology of Barrett's esophagus is still confusing.
  • Recent proposal of endoscopic evaluation of Barrett's esophagus is based on the endoscopic findings, not histologic findings.
  • In the development of adenocarcinoma of the esophagus, several steps of genetic abnormalities might be involved.
  • We still do not know whether we may experience an increase of adenocarcinoma of the esophagus in Japan or not.
  • [MeSH-major] Barrett Esophagus
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / etiology. Esophagitis, Peptic / complications. Esophagoscopy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101216.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


100. Włodarczyk J: [Barret esophagus--molecular biology]. Przegl Lek; 2008;65(2):73-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Barret esophagus--molecular biology].
  • Increasing incidence of adenocarcinoma of the esophagus is nowadays observed in western countries.
  • Estimation of the unique molecules may, in the future, lead to early diagnostics of pathological changes in the Barret esophagus and identification of the patient at risk from cancerogenesis.
  • The aim of this study is to explain terminology of Barret esophagus, basis of histopatology, diagnostics and to show molecules which have crucial significance in cancerogenesis.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / pathology. Esophageal Neoplasms / prevention & control. Genetic Markers
  • [MeSH-minor] Genes, Tumor Suppressor. Humans. Oncogenes / genetics. Risk Factors. Terminology as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663904.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 62
  •  go-up   go-down






Advertisement